WO2007135398A1 - Dérivés de l'indole - Google Patents

Dérivés de l'indole Download PDF

Info

Publication number
WO2007135398A1
WO2007135398A1 PCT/GB2007/001858 GB2007001858W WO2007135398A1 WO 2007135398 A1 WO2007135398 A1 WO 2007135398A1 GB 2007001858 W GB2007001858 W GB 2007001858W WO 2007135398 A1 WO2007135398 A1 WO 2007135398A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
formula
amino
heteroaryl
Prior art date
Application number
PCT/GB2007/001858
Other languages
English (en)
Inventor
Kevin Michael Foote
Edward Jolyon Griffen
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Priority to US12/301,722 priority Critical patent/US20090306126A1/en
Priority to JP2009511568A priority patent/JP2009537621A/ja
Priority to EP07732879A priority patent/EP2029593A1/fr
Publication of WO2007135398A1 publication Critical patent/WO2007135398A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention concerns certain novel indole derivatives, or pharmaceutically-acceptable salts thereof, which possess anti-tumour activity and are accordingly useful in methods of treatment of the human or animal body.
  • the invention also concerns processes for the manufacture of said indole derivatives, pharmaceutical compositions containing them and their use in therapeutic methods, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase, for example in the manufacture of medicaments for use in the prevention or treatment of cancers in a warm-blooded animal such as man, including use in the production of an anti-proliferative effect and use in the prevention or treatment of solid tumour disease.
  • a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene, that is a gene which, on activation, leads to the formation of malignant tumour cells (Bradshaw, Mutagenesis. 1986, 1, 91).
  • oncogenes give rise to the production of peptides which are receptors for growth factors. Activation of the growth factor receptor complex subsequently leads to an increase in cell proliferation. It is known, for example, that several oncogenes encode tyrosine kinase enzymes and that certain growth factor receptors are also tyrosine kinase enzymes (Yarden et ah, Ann. Rev.
  • Receptor tyrosine kinases are important in the transmission of biochemical signals which initiate cell replication. They are large enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor (EGF) and an intracellular portion which functions as a kinase to phosphorylate tyrosine amino acids in proteins and hence to influence cell proliferation.
  • EGF epidermal growth factor
  • Various classes of receptor tyrosine kinases are known (Wilks, Advances in Cancer Research. 1993, 60, 43-73) based on families of growth factors which bind to different receptor tyrosine kinases. The classification includes Class I receptor tyrosine kinases comprising the EGF family of receptor tyrosine kinases such as the EGF, TGF ⁇ , Neu and erbB receptors.
  • tyrosine kinases belong to the class of non-receptor tyrosine kinases which are located intracellularly and are involved in the transmission of biochemical signals such as those that influence tumour cell motility, dissemination and invasiveness and subsequently metastatic tumour growth.
  • Various classes of non-receptor tyrosine kinases are known including the Src family such as the Src, Lyn, Fyn and Yes tyrosine kinases.
  • kinases belong to the class of serine/threonine kinases which are located intracellularly and downstream of tyrosine kinase activation and are involved in the transmission of biochemical signals such as those that influence tumour cell growth.
  • serine/threonine signalling pathways include the Raf-MEK-ERK cascade and those downstream of the lipid kinase known as PI3K such as PDK-I, AKT and mTOR (Blume- Jensen and Hunter, Nature, 2001, 411, 355).
  • lipid kinases that belong to the class of lipid kinases are located intracellularly and are also involved in the transmission of biochemical signals such as those that influence tumour cell growth and invasiveness.
  • Various classes of lipid kinases are known including the phosphoinositide 3-kinase (abbreviated hereinafter to PI3K) family that is alternatively known as the phosphatidylinositol-3 -kinase family.
  • the PI3K family of lipid kinases is a group of enzymes that phosphorylate the 3-position of the inositol ring of phosphatidylinositol (abbreviated hereinafter to PI).
  • PI phosphatidylinositol
  • Three major groups of PI3K enzymes are known which are classified according to their physiological substrate specificity (Vanhaesebroeck et al, Trends in Biol. Sci.. 1997, 22, 267).
  • Class III PI3K enzymes phosphorylate PI alone.
  • Class II PI3K enzymes phosphorylate both PI and PI 4-phosphate [abbreviated hereinafter to PI(4)P].
  • Class I PDK enzymes phosphorylate PI, PI(4)P and PI 4,5-bisphos ⁇ hate [abbreviated hereinafter to PI(4,5)P2], although only PI(4,5)P2 is believed to be the physiological cellular substrate. Phosphorylation of PI(4,5)P2 produces the lipid second messenger PI 3,4,5-triphosphate [abbreviated hereinafter to PI(3,4,5)P3]. More distantly related members of this superfamily are Class IV kinases such as mTOR and DNA-dependent kinase that phosphorylate serine/threonine residues within protein substrates. The most studied and understood of these lipid kinases are the Class I PI3K enzymes.
  • Class I PI3K is a heterodimer consisting of a pi 10 catalytic subunit and a regulatory subunit, and the family is further divided into Class Ia and Class Ib enzymes on the basis of regulatory partners and mechanism of regulation.
  • Class Ia enzymes consist of three distinct catalytic subunits (pi 10a, pi lO ⁇ and pi 105) that dimerise with five distinct regulatory subunits (p85 ⁇ , p55 ⁇ , p50 ⁇ , p85 ⁇ and p55 ⁇ ), with all catalytic subunits being able to interact with all regulatory subunits to form a variety of heterodimers.
  • Class Ia PI3K are generally activated in response to growth factor-stimulation of receptor tyrosine kinases, via interaction of the regulatory subunit SH2 domains with specific phospho-tyrosine residues of the activated receptor or adaptor proteins such as IRS-I .
  • Both pi 10a and pi lO ⁇ are constitutively expressed in all cell types, whereas pi lO ⁇ expression is more restricted to leukocyte populations and some epithelial cells.
  • the single Class Ib enzyme consists of a pi lO ⁇ catalytic subunit that interacts with a pi 01 regulatory subunit.
  • GPCR G-protein coupled receptor
  • Tumour-related mutations in p85 ⁇ have also been identified in cancers such as those of the ovary and colon (Philp et al, Cancer Research. 2001, 61, 7426-7429).
  • activation of Class Ia PI3K contributes to tumourigenic events that occur upstream in signalling pathways, for example by way of ligand-dependent or ligand-independent activation of receptor tyrosine kinases, GPCR systems or integrins (Vara et al, Cancer Treatment Reviews, 2004, 30, 193-204).
  • upstream signalling pathways examples include over-expression of the receptor tyrosine kinase Erb2 in a variety of tumours leading to activation of PI3K-mediated pathways (Harari et al, Oncogene, 2000, 19, 6102-6114) and over-expression of the oncogene Ras (Kauffmann-Zeh et al, Nature, 1997, 385, 544-548).
  • Class Ia PI3Ks may contribute indirectly to tumourigenesis caused by various downstream signalling events.
  • loss of the effect of the PTEN tumour-suppressor phosphatase that catalyses conversion of PI(3,4,5)P3 back to PI(4,5)P2 is associated with a very broad range of tumours via deregulation of PI3K-mediated production of PI(3,4,5)P3 (Simpson and Parsons, Exp. Cell Res., 2001, 264, 29-41).
  • augmentation of the effects of other PI3K-mediated signalling events is believed to contribute to a variety of cancers, for example by activation of Akt (Nicholson and Anderson, Cellular Signalling, 2002, IA, 381-395).
  • Class Ia PI3K enzymes will also contribute to tumourigenesis via its function in tumour-associated stromal cells.
  • PI3K signalling is known to play an important role in mediating angiogenic events in endothelial cells in response to pro-angiogenic factors such as VEGF (Abid et al, Arterioscler. Thromb. Vase. Biol., 2004, 24, 294-300).
  • VEGF vascular endothelial cells
  • VEGF vascular endothelial growth factor
  • PI3K inhibitors should provide therapeutic benefit via inhibition of tumour cell invasion and metastasis.
  • Class I PI3K enzymes play an important role in the regulation of immune cells with PI3K activity contributing to pro-tumourigenic effects of inflammatory cells (Coussens and Werb, Nature, 2002, 420, 860-867).
  • pharmacological inhibitors of Class I PI3K enzymes should be of therapeutic value for treatment of the various forms of the disease of cancer comprising solid tumours such as carcinomas and sarcomas and the leukaemias and lymphoid malignancies.
  • inhibitors of Class I PI3K enzymes should be of therapeutic value for treatment of, for example, cancer of the breast, colorectum, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer) and prostate, and of cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix and vulva, and of leukaemias (including ALL and CML), multiple myeloma and lymphomas.
  • cancer of the breast, colorectum, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer) and prostate and of cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix and vulva,
  • POK ⁇ the Class Ib PI3K
  • GPCRs GPCRs
  • neutrophils and macrophages derived from PI3K ⁇ -deficient animals failed to produce PI(3,4,5)P 3 in response to stimulation with various chemotactic substances (such as IL-8, C5a, fMLP and MIP-Ia), whereas signalling through protein tyrosine kinase-coupled receptors to Class Ia PBKs was intact (Hirsch et al, Science, 2000, 287(5455), 1049-1053; Li et al, Science, 2002, 287(5455), 1046-1049; Sasaki et al, Science 2002, 287(5455), 1040-1046).
  • PI(3,4,5)P 3 -mediated phosphorylation of PKB was not initiated by these GPCR ligands in PI3K ⁇ -null cells.
  • PDK ⁇ is the sole PI3K isoform that is activated by GPCRs in vivo.
  • murine bone marrow-derived neutrophils and peritoneal macrophages from wild-type and PI3K ⁇ " ⁇ mice were tested in vitro, a reduced, but not completely abrogated, performance in chemotaxis and adherence assays was observed.
  • Class I PDK enzymes play a role in other diseases (Wymann et al, Trends in Pharmacological Science. 2003, 24, 366-376). Both Class Ia PDK enzymes and the single Class Ib enzyme have important roles in cells of the immune system (Koyasu, Nature Immunology, 2003, 4, 313-319) and thus they are therapeutic targets for inflammatory and allergic indications. Inhibition of PBK is also useful to treat cardiovascular disease via anti-inflammatory effects or directly by affecting cardiac myocytes (Prasad et ah, Trends in Cardiovascular Medicine, 2003, 13_, 206-212). Thus inhibitors of Class I PI3K enzymes are expected to be of value in the prevention and treatment of a wide variety of diseases in addition to cancer.
  • PI3K inhibitors LY294002 and wortmannin. Although use of those compounds may suggest a role for PI3K in a cellular event, they are not sufficiently selective within the PI3K family to allow dissection of the individual roles of the family members. For this reason, more potent and selective pharmaceutical PI3K inhibitors would be useful to allow a more complete understanding of PI3K function and to provide useful therapeutic agents.
  • PI3K inhibitors for use in the treatment of cancer, inflammatory or obstructive airways diseases, immune or cardiovascular diseases.
  • the disclosed compounds include :-
  • tumour-suppressor genes contributes to the formation of malignant tumours, for example by way of increased cell proliferation or increased cell survival.
  • signalling pathways mediated by the PI3K/mT0R families have a central role in a number of cell processes including proliferation and survival, and deregulation of these pathways is a causative factor in a wide spectrum of human cancers and other diseases.
  • the mammalian target of the macrolide antibiotic Rapamycin is the enzyme mTOR that belongs to the phosphatidylinositol (PI) kinase-related kinase (PIKK) family of protein kinases, which includes ATM, ATR, DNA-PK and hSMG-1.
  • PI phosphatidylinositol
  • PIKK phosphatidylinositol
  • mTOR phosphatidylinositol family of protein kinases, which includes ATM, ATR, DNA-PK and hSMG-1.
  • PIKK phosphatidylinositol
  • PIKK phosphatidylinositol
  • PIKK phosphatidylinositol
  • mTOR like other PIKK family members, does not possess detectable lipid kinase activity, but instead functions as a serine/threonine kinase.
  • Rapamycin first binds to the 12 kDa immunophilin FK506-binding protein (FKBP 12) and this complex inhibits mTOR signalling (Tee and Blenis, Seminars in Cell and Developmental Biology, 2005, V6, 29-37).
  • mTOR protein consists of a catalytic kinase domain, an FKBP12-Rapamycin binding (FRB) domain, a putative repressor domain near the C-terminus and up to 20 tandemly-repeated HEAT motifs at the TV-terminus, as well as FRAP-ATM-TRRAP (FAT) and FAT C-terminus domain (Huang and Houghton, Current Opinion in Pharmacology. 2003, 3, 371-377).
  • mTOR kinase is a key regulator of cell growth and has been shown to regulate a wide range of cellular functions including translation, transcription, mRNA turnover, protein stability, actin cytoskeleton reorganisation and autophagy (Jacinto and Hall, Nature Reviews Molecular and Cell Biology, 2005, 4, 117-126).
  • mTOR kinase integrates signals from growth factors (such as insulin or insulin-like growth factor) and nutrients (such as amino acids and glucose) to regulate cell growth.
  • growth factors such as insulin or insulin-like growth factor
  • nutrients such as amino acids and glucose
  • mTOR kinase The most well characterised function of mTOR kinase in mammalian cells is regulation of translation through two pathways, namely activation of ribosomal S6K1 to enhance translation of mRNAs that bear a 5 '-terminal oligopyrimidine tract (TOP) and suppression of 4E-BP1 to allow CAP-dependent mRNA translation.
  • TOP 5 '-terminal oligopyrimidine tract
  • PI3K pathway components of the PI3K pathway that are mutated in different human tumours include activating mutations of growth factor receptors and the amplification and/or overexpression of PI3K and Akt.
  • endothelial cell proliferation may also be dependent upon mTOR signalling.
  • Endothelial cell proliferation is stimulated by vascular endothelial cell growth factor (VEGF) activation of the PI3K-Akt-mTOR signalling pathway (Dancey, Expert Opinion on Investigational Drugs, 2005, 14, 313-328).
  • VEGF vascular endothelial cell growth factor
  • mTOR kinase signalling is believed to partially control VEGF synthesis through effects on the expression of hypoxia- inducible factor- l ⁇ (HIF- l ⁇ ) (Hudson et ah, Molecular and Cellular Biology, 2002, 22, 7004- 7014).
  • tumour angiogenesis may depend on mTOR kinase signalling in two ways, through hypoxia-induced synthesis of VEGF by tumour and stromal cells, and through VEGF stimulation of endothelial proliferation and survival through PI3K-Akt-mTOR signalling.
  • tumour suppressor proteins such as TSCl, TSC2, PTEN and LKBl tightly control mTOR kinase signalling. Loss of these tumour suppressor proteins leads to a range of hamartoma conditions as a result of elevated mTOR kinase signalling (Tee and Blenis, Seminars in Cell and Developmental Biology, 2005, 1_6, 29-37).
  • Syndromes with an established molecular link to dysregulation of mTOR kinase include Koz-Jeghers syndrome (PJS), Cowden disease, Bannayan-Riley- Ruvalcaba syndrome (BRRS), Proteus syndrome, Lhermitte-Duclos disease and TSC (Inoki et aL, Nature Genetics, 2005, 37, 19-24). Patients with these syndromes characteristically develop benign hamartomatous tumours in multiple organs.
  • Rapamycin has been demonstrated to be a potent immunosuppressant by inhibiting antigen-induced proliferation of T cells, B cells and antibody production (Sehgal, Transplantation Proceedings, 2003, 35_, 7S- 14S) and thus mTOR kinase inhibitors may also be useful immunosuppressives.
  • Inhibition of the kinase activity of mTOR may also be useful in the prevention of restenosis, that is the control of undesired proliferation of normal cells in the vasculature in response to the introduction of stents in the treatment of vasculature disease (Morice et ah, New England Journal of Medicine, 2002, 346, 1773-1780).
  • the Rapamycin analogue, everolimus can reduce the severity and incidence of cardiac allograft vasculopathy (Eisen et al., New England Journal of Medicine. 2003, 349, 847-858).
  • mTOR kinase inhibitors are expected to be of value in the prevention and treatment of a wide variety of diseases in addition to cancer.
  • indole derivatives of the present invention have inhibitory activity against the mTOR PI kinase-related kinase family of enzymes as well as against PI3K enzymes.
  • indole derivatives possess potent anti-tumour activity, being useful in inhibiting the uncontrolled cellular proliferation which arises from malignant disease.
  • the compounds disclosed in the present invention possess pharmacological activity only by virtue of an effect on a single biological process, it is believed that the compounds provide an anti-tumour effect by way of inhibition of Class I PI3K enzymes, particularly by way of inhibition of the Class Ia PI3K enzymes and/or the Class Ib PDK enzyme, more particularly by way of inhibition of the Class Ia PBK enzymes.
  • the compounds of the present invention are also useful in inhibiting the uncontrolled cellular proliferation which arises from various non-malignant diseases such as inflammatory diseases (for example rheumatoid arthritis and inflammatory bowel disease), fibrotic diseases (for example hepatic cirrhosis and lung fibrosis), glomerulonephritis, multiple sclerosis, psoriasis, benign prostatic hypertrophy (BPH), hypersensitivity reactions of the skin, blood vessel diseases (for example atherosclerosis and restenosis), allergic asthma, insulin-dependent diabetes, diabetic retinopathy and diabetic nephropathy.
  • inflammatory diseases for example rheumatoid arthritis and inflammatory bowel disease
  • fibrotic diseases for example hepatic cirrhosis and lung fibrosis
  • glomerulonephritis for example hepatic cirrhosis and lung fibrosis
  • multiple sclerosis multiple sclerosis
  • psoriasis glomerulonephritis
  • the compounds of the present invention possess potent inhibitory activity against Class I PI3K enzymes, particularly against Class Ia PI3K enzymes, whilst possessing less potent inhibitory activity against tyrosine kinase enzymes such as the receptor tyrosine kinases, for example EGF receptor tyrosine kinase and/or VEGF receptor tyrosine kinase, or against non-receptor tyrosine kinases such as Src.
  • the receptor tyrosine kinases for example EGF receptor tyrosine kinase and/or VEGF receptor tyrosine kinase
  • non-receptor tyrosine kinases such as Src.
  • certain compounds of the present invention possess substantially better potency against Class I PI3K enzymes, particularly against Class Ia PI3K enzymes, than against EGF receptor tyrosine kinase or VEGF receptor tyrosine kinase or Src non-receptor tyrosine kinase.
  • Such compounds possess sufficient potency against Class I PI3K enzymes that they may be used in an amount sufficient to inhibit Class I PI3K enzymes, particularly to inhibit Class Ia PI3K enzymes, whilst demonstrating little activity against EGF receptor tyrosine kinase or VEGF receptor tyrosine kinase or Src non-receptor tyrosine kinase.
  • Ring A is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl,
  • each R 1 group that is present is selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, (l-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (l- ⁇ C)alkoxy, (l-6C)alkylthio, (l- ⁇ C)alkylsulphinyl, (l-6C)alky Sulphonyl, (l-6C)alkylamino, di-[(l-6C)alkyl]amino, hydroxy-(2-6C)alkoxy and (l-6C)alkoxy-(2-6C)alkoxy; the R 2 group is selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, (l-8C)alkyl, (2-8C)alkenyl, (2
  • X 1 is a direct bond or is selected from O, S, SO, SO 2 , N(R 4 ), CO, CH(OR 4 ), CON(R 4 ), N(R 4 )CO, N(R 4 )CON(R 4 ), SO 2 N(R 4 ), N(R 4 )SO 2 , C(R 4 ) 2 O, C(R 4 ) 2 S and C(R 4 ) 2 N(R 4 ), wherein each R 4 group is hydrogen, (l-8C)alkyl or (2-6C)alkanoyl, and Q 1 is aryl, aryl-(l-6C)alkyl, aryloxy-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any CH, CH 2
  • X 2 is a direct bond or is selected from O, S, SO, SO 2 , N(R 5 ), CO, CH(OR 5 ), CON(R 5 ), N(R 5 )CO, SO 2 N(R 5 ), N(R 5 )SO 2 , C(R 5 ) 2 O, C(R 5 ) 2 S and C(R 5 ) 2 N(R 5 ), wherein each R group is hydrogen or (l-8C)alkyl, and Q is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl group within a R 2 group optionally bears 1, 2 or 3 substituents
  • X 3 is a direct bond or is selected from O and N(R 7 ), wherein R 7 is hydrogen or (l-8C)alkyl, and R 6 is halogeno-(l-6C)alkyl, hydroxy-(l-6C)alkyl, (l-6C)alkoxy-(l-6C)alkyl, (l-6C)alkylthio-(l-6C)alkyl, (l-6C)alkylsulphinyl-(l-6C)alkyl, (l-6C)alkylsulphonyl- (l-6C)alkyl, cyano-(l-6C)alkyl, amino-(l-6C)alkyl, (l-6C)alkylamino-(l-6C)alkyl, di-[(l-6C)alkyl]amino-(l-6C)alkyl, (2-6C)alkanoylamino-(l-6C)alkyl or N-(l-6
  • X 4 is a direct bond or is selected from O, CO and N(R 8 ), wherein R 8 is hydrogen or (l-8C)alkyl
  • Q 3 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and the Q 3 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, cyano, hydroxy, (l-8C)alkyl, (l-6C)alkoxy, (l-6C)alkylthio, (l-6C)alkylsulphinyl, (l-6C)alkylsul ⁇ honyl and (2-6C)alkanoyl, and wherein any heterocyclyl group within the R 2 group
  • Gi is CH or N; n is 0, 1, 2 or 3; and each R 3 group that is present, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, carboxy, carbamoyl, (l- ⁇ C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (l-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (l-6C)alkylthio, (l- ⁇ C)alkylsulphinyl, (l-6C)alkylsulphonyl, (l-6C)alkylamino, di- [( 1 -6C)alkyl]amino, ( 1 -6C)alkoxycarbonyl, N-(I -6C)alkylcarbamoyl, iV,iV-di-[(l-6C)alkyl]carbamoyl, (2-6C)al
  • X 5 is selected from O, S, SO, SO 2 , N(R 9 ), CON(R 9 ), N(R 9 )CO, N(R 9 )CON(R 9 ), SO 2 N(R 9 ), N(R 9 )SO 2 , OC(R 9 ) 2 , SC(R 9 ) 2 and N(R 9 )C(R 9 ) 2 , wherein each R 9 group is hydrogen, (l-8C)alkyl or (2-6C)alkanoyl, and Q 4 is aryl, aryl-(l-6C)alkyl, aryloxy-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any CH, CH 2 or CH 3 group within a R 3 group
  • R 10 _ ⁇ 6 _ wherein X 6 is a direct bond or is selected from O and N(R 11 ), wherein R 11 is hydrogen or (l-8C)alkyl, and R 10 is halogeno-(l-6C)alkyl, hydroxy-(l-6C)alkyl, (l-6C)alkoxy-(l-6C)alkyl, (l-6C)alkylthio-(l-6C)alkyl, (l-6C)alkylsulphinyl-(l-6C)alkyl, (l-6C)alkylsulphonyl- (l-6C)alkyl, cyano-(l-6C)alkyl, amino-(l-6C)alkyl, (l-6C)alkylamino-(l-6C)alkyl, di-[(l-6C)alkyl]amino-(l-6C)alkyl, (2-6C)alkanoylamino-(l-6C)alkyl or N-(
  • X 7 is a direct bond or is selected from O, S 5 SO, SO 2 , N(R 12 ), CO, CON(R 12 ) and N(R 12 )C0, wherein R 12 is hydrogen or (l-8C)alkyl
  • Q 5 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl group within a R 3 group optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, trifluoromethoxy, carboxy, carbamoyl, (l-8
  • Q 6 -X 9 - wherein X 9 is a direct bond or is selected from O, CO and N(R 15 ), wherein R 15 is hydrogen or (l-8C)alkyl, and Q 6 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and the Q 6 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, cyano, hydroxy, (l-8C)alkyl, (l-6C)alkoxy, (l-6C)alkylthio, (l-6C)alkylsulphinyl, (l- ⁇ C)alkylsul ⁇ honyl and (2-6C)alkanoyl, and wherein any heterocyclyl group within the R
  • (l-8C)alkyl includes both straight-chain and branched-chain alkyl groups such as propyl, isopropyl and tert-butyl, and also (3-8C)cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, and also (3-6C)cycloalkyl-(l-2C)alkyl groups such as cyclopropylmethyl, 2-cyclopropylethyl, cyclobutylmethyl, 2-cyclobutylethyl, cyclopentylmethyl, 2-cyclopentylethyl, cyclohexylmethyl and 2-cyclohexylethyl.
  • references to individual alkyl groups such as "propyl” are specific for the straight-chain version only
  • references to individual branched-chain alkyl groups such as “isopropyl” are specific for the branched-chain version only
  • references to individual cycloalkyl groups such as “cyclopentyl” are specific for that 5-membered ring only.
  • (l- ⁇ C)alkoxy includes (3-6C)cycloalkyloxy groups and (3-5C)cycloalkyl-(l-2C)alkoxy groups, for example methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cyclopropylmethoxy, 2-cyclopropylethoxy, cyclobutylmethoxy, 2-cyclobutylethoxy and cyclopentylmethoxy;
  • (l-6C)alkylamino includes (3-6C)cycloalkylamino groups and (3-5C)cycloalkyl- (l-2C)alkylamino groups, for example methylamino, ethylamino, propylamino, cyclopropylamino, cyclobutylamino, cyclohexylamino, cyclopropy
  • the invention includes in its definition any such optically active or racemic form which possesses the above-mentioned activity.
  • the synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form.
  • the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.
  • tautomerism may affect heterocyclic groups within the R 2 and R 3 groups that bear 1 or 2 oxo or thioxo substituents.
  • present invention includes in its definition any such tautomeric form, or a mixture thereof, which possesses the above-mentioned activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings or named in the Examples.
  • Ring A is, for example, a 3-pyridyl group
  • the locant indicates the position that is linked to the 5-position on the lH-pyrrolo[2,3- ⁇ ]pyridine ring (when G 1 is CH).
  • any R 1 group that is present on Ring A may be located at any available position on any of said 6-membered rings.
  • the R 1 groups may be the same or different.
  • m is 0 and there is no R 1 group present on Ring A.
  • the single R 1 group is located at the 2-, 3- or 4-position on Ring A [the locant being counted from the Ring A position that is linked to the 5-position on the lH-pyrrolo[2,3 ⁇ £>]pyridine ring (when G 1 is CH)].
  • the R 2 group that is present on Ring A may be located at any available position on any of said 6-membered rings.
  • the R 2 group is located at the 3- or 4-position on Ring A [the locant being counted from the Ring A position that is linked to the 5-position on the lH " -pyrrolo[2,3-&]pyridine ring (when Gi is CH)]. More conveniently, the R 2 group is located at the 3 -position on Ring A.
  • any R 3 group that is present on the l//-pyrrolo[2,3-Z>]pyridine ring may be located at any available position on said bicyclic ring, that is any such R 3 group may be located on the pyrrole ring portion of the l//-pyrrolo[2,3-Z>]pyridine ring (when Gi is CH) or on the pyridine ring portion thereof.
  • the R 3 groups may be the same or different.
  • n is 0 and there is no R 3 group present.
  • any R 3 group that is present is located at the 2- or 3-position on the lH " -pyrrolo[2,3-&]pyridine ring (when Gi is CH) or at the 4- or 6-position thereof.
  • any R 3 group that is present is located at the 2-position on the 3H-imidazo[4,5-Z?]pyridine ring (when G 1 is N) or at the 5- or 7-position thereof. More conveniently, the R 3 group is located at the 6-position on the lH-pyrrolo[2,3- ⁇ ]pyridine ring (when G 1 is CH). Alternatively, the R 3 group is located at the 5-position on the 3i ⁇ -imidazo[4,5-b]pyridine ring (when G 1 is N).
  • any suitable R 3 group may be located on the nitrogen atom at the 1 -position of the lH " -pyrrolo[2,3-Z>]pyridine ring (when G 1 is CH) or at the 3-position of the 3H-imidazo[4,5-b]pyridine ring (when G 1 is N) or at the 1 -position if the lH-imidazo[4,5- ⁇ ]pyridine ring tautomer is present.
  • a suitable R 3 group that may be located on such a nitrogen atom is a group such as a (l- ⁇ C)alkyl group or a (2-6C)alkanoyl group that forms a relatively stable compound.
  • an example of a less suitable R 3 group is, for example, a halogeno, hydroxy or (l- ⁇ C)alkoxy group.
  • Suitable values for the generic radicals referred to above include those set out below.
  • a suitable value for any one of the 'Q' groups (Q 1 to Q 6 ) when it is aryl or for the aryl group within a 'Q' group is, for example, phenyl or naphthyl, preferably phenyl.
  • a suitable value for any one of the 'Q' groups (Q 1 to Q 6 ) when it is (3-8C)cycloalkyl or for the (3-8C)cycloalkyl group within a 'Q' group is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptyl or cyclooctyl, or a benzo-fused (3-8C)cycloalkyl group such as indanyl or tetrahydronaphthyl.
  • a suitable value for any one of the 'Q' groups (Q 1 to Q 6 ) when it is heteroaryl or for the heteroaryl group within a 'Q' group is, for example, an aromatic 5- or 6-membered monocyclic ring or a 9- or 10-membered bicyclic ring with up to five ring heteroatoms selected from oxygen, nitrogen and sulphur, for example furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, benzothienyl, benzoxazolyl, benzimidazolyl, be
  • a suitable value for any one of the 'Q' groups (Q 1 to Q 6 ) when it is heterocyclyl or for the heterocyclyl group within a 'Q' group is, for example, a non-aromatic saturated or partially saturated 3 to 10 membered monocyclic or bicyclic ring with up to five heteroatoms selected from oxygen, nitrogen and sulphur, for example oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, oxepanyl, tetrahydrothienyl, 1,1-dioxotetrahydrothienyl, tetrahydrothiopyranyl, 1,1-dioxotetrahydrothiopyranyl, azetidinyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl,
  • a suitable value for such a group which bears 1 or 2 oxo or thioxo substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxooxazolidinyl, 2-oxothiazolidinyl, 2-oxopiperidinyl, 4-oxo-l,4-dihydropyridinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.
  • a suitable value for a 'Q' group when it is heteroaryl-(l-6C)alkyl is, for example, heteroarylmethyl, 2-heteroarylethyl and 3-heteroarylpropyl.
  • the invention comprises corresponding suitable values for 'Q' groups when, for example, rather than a heteroaryl-(l-6C)alkyl group, an aryl-(l-6C)alkyl, (3-8C)cycloalkyl-(l-6C)alkyl or heterocyclyl-(l-6C)alkyl group is present.
  • Suitable values for any of the 'R' groups (R 1 to R 15 ), or for various groups within a R 1 , R 2 or R 3 group, or for various groups within any of the 'Q' groups (Q 1 to Q 6 ) include :- for halogeno fluoro, chloro, bromo and iodo; for (l-8C)alkyl: methyl, ethyl, propyl, isopropyl, tert-butyl, cyclobutyl, cyclohexyl, cyclohexylmethyl and 2-cyclopropylethyl; for (2-8C)alkenyl: vinyl, isopropenyl, allyl and but-2-enyl; for (2-8C)alkynyl: ethynyl, 2-propynyl and but-2-ynyl; for (l-6C)alkoxy: methoxy, ethoxy, propoxy, isopropoxy and butoxy; for (2-6C
  • N-ethyl-N-methylamino and diisopropylamino for (l- ⁇ C)alkoxycarbonyl: methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and fert-butoxycarbonyl; for N-( 1 -6C)alkylcarbamoy 1 : N-methylcarbamoyl, JV-ethylcarbamoyl and
  • N-methy lethanesulphony lamino for hydroxy-(2-6C)alkoxy: 2-hydroxyethoxy and 3-hydroxypropoxy; for (l-6C)alkoxy-(2-6C)alkoxy: 2-methoxyethoxy, 2-ethoxyethoxy,
  • amino-(l-6C)alkyl aminomethyl, 2-aminoethyl, 1-aminoethyl,
  • the R 2 group is a group of the formula -X'-Q 1 and, for example, X 1 is a CON(R 4 ) linking group, it is the carbon atom, not the nitrogen atom, of the CON(R 4 ) linking group which is attached to Ring A and the nitrogen atom is attached to the Q 1 group.
  • R 2 is a group of the formula -X ⁇ Q 1 and, for example, X 1 is a C(R 4 ) 2 O linking group, it is the carbon atom, not the oxygen atom, of the C(R 4 ) 2 O linking group which is attached to Ring A and the oxygen atom is linked to the Q 1 group.
  • a CH 3 group within a R 2 group bears a group of the formula -X 2 -Q 2 and, for example, X 2 is a C(R 5 ) 2 O linking group, it is the carbon atom, not the oxygen atom, of the C(R 5 ) 2 O linking group which is attached to the CH 3 group and the oxygen atom is linked to the Q 2 group.
  • R 3 is a group of the formula Q 4 -X 5 - and, for example, X 5 is a N(R 9 )C0 linking group
  • X 5 is a N(R 9 )C0 linking group
  • it is the carbon atom, not the nitrogen atom, of the N(R 9 )C0 linking group which is attached to the lH " -pyrrolo[2,3- ⁇ ]pyridine ring (when G 1 is CH) and the nitrogen atom of the N(R 9 )C0 linking group is attached to the Q 4 group.
  • An equivalent convention is applicable to the linkages of the Q 5 -X 7 - group.
  • any CH, CH 2 or CH 3 group within a R 2 group or within a R 3 group optionally bears a substituent as defined hereinbefore on each said CH, CH 2 or CH 3 group, it is to be understood that said CH and CH 2 groups form component parts of an acyclic R 2 or R 3 group i.e. said CH and CH 2 groups do not form ring atoms within an aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl ring.
  • any CH, CH 2 or CH 3 group within a R 2 group or within a R 3 group optionally bears on each said CH, CH 2 or CH 3 group one or more halogeno or (l-8C)alkyl substituents, there is suitably a single halogeno or (l-8C)alkyl substituent present on each said CH group, there are suitably 1 or 2 such substituents present on each said CH 2 group and there are suitably 1, 2 or 3 such substituents present on each said CH 3 group.
  • any CH, CH 2 or CH 3 group within a R 2 group or within a R 3 group optionally bears on each said CH, CH 2 or CH 3 group a substituent as defined hereinbefore
  • suitable R 2 or R 3 groups so formed include, for example, hydroxy-substituted (l-8C)alkyl groups such as hydroxymethyl, 1 -hydroxy ethyl and 2-hydroxyethyl, hydroxy-substituted (l- ⁇ C)alkoxy groups such as 2-hydroxypropoxy and 3-hydroxypropoxy, (l-6C)alkoxy-substituted (l-6C)alkoxy groups such as 2-methoxyethoxy and 3-ethoxypropoxy, hydroxy-substituted amino-(2-6C)alkoxy groups such as 3-amino-2 ⁇ hydroxypropoxy, hydroxy-substituted (l-6C)alkylamino-(2-6C)alkoxy groups such as 2-hydroxy-3-methylaminopropoxy, hydroxy-sub
  • any CH, CH 2 or CH 3 group within a R 2 or R 3 group optionally bears on each said CH, CH 2 or CH 3 group a substituent as defined hereinbefore, such an optional substituent may be present on a CH, CH 2 or CH 3 group within the hereinbefore defined substituents that may be present on an aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl group within a R 2 or R 3 group.
  • R 2 includes an aryl or heteroaryl group that is substituted by a (l-8C)alkyl group
  • the (l-8C)alkyl group may be optionally substituted on a CH, CH 2 or CH 3 group therein by one of the hereinbefore defined substituents therefor.
  • R 2 includes a heteroaryl group that is substituted by, for example, a (l-6C)alkylamino-(l-6C)alkyl group
  • the terminal CH 3 group of the (l-6C)alkylamino group may be further substituted by, for example, a (l-6C)alkylsulphonyl group or a (2-6C)alkanoyl group.
  • the R 2 group may be a heteroaryl group such as a thienyl group that is substituted by a N-(2-methylsul ⁇ honyletliyl)aminomethyl group such that R 2 is, for example, a 5-[iV-(2-methylsulphonylethyl)ammomethyl]thien-2-yl group.
  • R 2 includes a heterocyclyl group such as a piperidinyl or piperazinyl group that is substituted on a nitrogen atom thereof by, for example, a (2-6C)alkanoyl group
  • the terminal CH 3 group of the (2-6C)alkanoyl group may be further substituted by, for example, a di-[(l-6C)alkyl]amino group.
  • the R 2 group may be a N-(2-dimethylaminoacetyl)piperidin-4-yl group or a 4-(2-dimethylaminoacetyl)piperazin-l-yl group.
  • a suitable pharmaceutically-acceptable salt of a compound of the Formula I is, for example, an acid-addition salt of a compound of the Formula I, for example an acid-addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric, trifluoroacetic, citric or maleic acid; or, for example, a salt of a compound of the Formula I which is sufficiently acidic, for example an alkali or alkaline earth metal salt such as a calcium or magnesium salt, or an ammonium salt, or a salt with an organic base such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
  • a further suitable pharmaceutically-acceptable salt of a compound of the Formula I is, for example, a salt formed within the human or animal body after administration of a compound of the Formula I.
  • a suitable pharmaceutically-acceptable solvate of a compound of the Formula I also forms an aspect of the present invention.
  • a suitable pharmaceutically-acceptable solvate is, for example, a hydrate such as a hemi-hydrate, a mono-hydrate, a di-hydrate or a tri-hydrate or an alternative quantity thereof.
  • a suitable pharmaceutically-acceptable pro-drug of a compound of the Formula I also forms an aspect of the present invention.
  • the compounds of the invention may be administered in the form of a pro-drug, that is a compound that is broken down in the human or animal body to release a compound of the invention.
  • a pro-drug may be used to alter the physical properties and/or the pharmacokinetic properties of a compound of the invention.
  • a pro-drug can be formed when the compound of the invention contains a suitable group or substituent to which a property-modifying group can be attached.
  • pro-drugs examples include in vivo cleavable ester derivatives that may be formed at a carboxy group or a hydroxy group in a compound of the Formula I and in vivo cleavable amide derivatives that may be formed at a carboxy group or an amino group in a compound of the Formula I.
  • the present invention includes those compounds of the Formula I as defined hereinbefore when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a pro-drug thereof. Accordingly, the present invention includes those compounds of the Formula I that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of the Formula I may be a synthetically-produced compound or a metabolically-produced compound.
  • a suitable pharmaceutically-acceptable pro-drug of a compound of the Formula I is one that is based on reasonable medical judgement as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity.
  • pro-drug Various forms of pro-drug have been described, for example in the following documents :- a) Methods in Enzvmology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) Design of Pro-drags, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drag Design and Development, edited by Krogsgaard-Larsen and
  • H. Bundgaard Chapter 5 "Design and Application of Pro-drugs", by H. Bundgaard p. 113-191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya, et al, Chem. Pharm. Bull.. 32, 692 (1984); g) T. Higuchi and V. Stella, "Pro-Drugs as Novel Delivery Systems", A.C.S. Symposium Series, Volume 14; and h) E. Roche (editor), "Bioreversible Carriers in Drug Design", Pergamon Press, 1987.
  • a suitable pharmaceutically-acceptable pro-drug of a compound of the Formula I that possesses a carboxy group is, for example, an in vivo cleavable ester thereof.
  • An in vivo cleavable ester of a compound of the Formula I containing a carboxy group is, for example, a pharmaceutically-acceptable ester which is cleaved in the human or animal body to produce the parent acid.
  • Suitable pharmaceutically-acceptable esters for carboxy include (l-6C)alkyl esters such as methyl, ethyl and tert-bntyl, (l-6C)alkoxymethyl esters such as methoxymethyl esters, (l-6C)alkanoyloxymethyl esters such as pivaloyloxymethyl esters, 3-phthalidyl esters, (3-8C)cycloalkylcarbonyloxy-(l-6C)alkyl esters such as cyclopentylcarbonyloxymethyl and 1-cyclohexylcarbonyloxyethyl esters, 2-oxo-l,3-dioxolenylmethyl esters such as 5-methyl-2-oxo-l,3-dioxolen-4-ylmethyl esters and (l-6C)alkoxycarbonyloxy-(l-6C)alkyl esters such as methoxycarbonyloxymethyl and 1-methoxycarbonyloxy ethyl esters
  • a suitable pharmaceutically-acceptable pro-drug of a compound of the Formula I that possesses a hydroxy group is, for example, an in vivo cleavable ester or ether thereof.
  • An in vivo cleavable ester or ether of a compound of the Formula I containing a hydroxy group is, for example, a pharmaceutically-acceptable ester or ether which is cleaved in the human or animal body to produce the parent hydroxy compound.
  • Suitable pharmaceutically-acceptable ester forming groups for a hydroxy group include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters).
  • ester forming groups for a hydroxy group include (l-lOC)alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, (l-lOC)alkoxycarbonyl groups such as ethoxycarbonyl, N, N- [di-(l-4C)alkyl] carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups.
  • (l-lOC)alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups
  • (l-lOC)alkoxycarbonyl groups such as ethoxycarbonyl, N, N- [di-(l-4C)alkyl] carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups.
  • Suitable pharmaceutically-acceptable ether forming groups for a hydroxy group include ⁇ -acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl groups.
  • a suitable pharmaceutically-acceptable pro-drug of a compound of the Formula I that possesses a carboxy group is, for example, an in vivo cleavable amide thereof, for example an amide formed with an amine such as ammonia, a (l-4C)alkylamine such as methylamine, a di-(l-4C)alkylamine such as dimethylamine, N-ethyl-iV-methylamine or diethylamine, a (l-4C)alkoxy-(2-4C)alkylamine such as 2-methoxyethylamine, aphenyl-(l-4C)alkylamine such as benzylamine and amino acids such as glycine or an ester thereof.
  • an amine such as ammonia
  • a (l-4C)alkylamine such as methylamine
  • a di-(l-4C)alkylamine such as dimethylamine, N-ethyl-iV-methylamine or diethylamine
  • a suitable pharmaceutically-acceptable pro-drug of a compound of the Formula I that possesses an amino group is, for example, an in vivo cleavable amide derivative thereof.
  • Suitable pharmaceutically-acceptable amides from an amino group include, for example an amide formed with (l-lOC)alkanoyl groups such as an acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups.
  • ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin- 1 -ylmethyl and 4-( 1 -4C)alkylpiperazin- 1 -ylmethyl.
  • the in vivo effects of a compound of the Formula I may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of the Formula I. As stated hereinbefore, the in vivo effects of a compound of the Formula I may also be exerted by way of metabolism of a precursor compound (a pro-drug).
  • Particular novel compounds of the invention include, for example, indole derivatives of the Formula I, or pharmaceutically-acceptable salts thereof, wherein, unless otherwise stated, each of Ring A, m, R 1 , R 2 , n, R 3 and G 1 has any of the meanings defined hereinbefore or in paragraphs (a) to (mm) hereinafter.
  • Particular novel compounds of the invention also include, for example, indole derivatives of any of the Formulae II to XI, or pharmaceutically- acceptable salts thereof, wherein, unless otherwise stated, each of m, R 1 , R 2 , n, R 3 and G) has any of the meanings defined hereinbefore or within appropriate paragraphs selected from paragraphs (a) to (mm) hereinafter :-
  • Ring A is a 2-pyridyl or 3-pyridyl group
  • Ring A is a 3-pyridyl group
  • Ring A is a 2-pyrazinyl group
  • Ring A is a 4-pyridyl or 4-pyrimidinyl group
  • Ring A is a 5-pyrimidinyl group
  • Ring A is a 3-pyridazinyl or 4-pyridazinyl group
  • each R 1 group that is present which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, hydroxy, (l- ⁇ C)alkyl, (2-6C)alkenyl,
  • m is 1 and the R 1 group is selected from halogeno, trifluoromethyl, cyano, hydroxy,
  • Q) m is 1 and the R 1 group is selected from halogeno, (l-6C)alkyl and (l-6C)alkoxy;
  • (k) m is 1 and the R 1 group is selected from fluoro, chloro, bromo, methyl, ethyl and methoxy;
  • m is 0 or m is 1 and the R 1 group is selected from fluoro, chloro, bromo, trifluoromethyl, cyano, methyl, ethyl, methoxy, ethoxy and methylsulphonyl;
  • (m) m is 0 or m is 1 and the R 1 group is selected from fluoro, chloro, bromo, methyl, ethyl and methoxy;
  • the R 2 group is selected from halogeno, trifluoromethyl, cyano, hydroxy, amino,
  • N-(l-6C)alkyl-(l-6C)alkanesulphonylamino or from a group of the formula :
  • X 1 is selected from O, S, SO, SO 2 , N(R 4 ), CO, CON(R 4 ), N(R 4 )C0, N(R 4 )CON(R 4 ), SO 2 N(R 4 ) and N(R 4 )SO 2 , wherein each R 4 group is hydrogen, (l-8C)alkyl or (2-6C)alkanoyl, and Q 2 is aryl, aryl-(l-6C)alkyl, aryloxy-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl- (l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any CH, CH 2 or CH 3 group within a R 2 group optionally bears on each said CH, CH 2 or CH 3 group one or more halogeno or (l-8C)alkyl
  • X 2 is a direct bond or is selected from O, S, SO, SO 2 , N(R 5 ) and CO, wherein R 5 is hydrogen or (l-8C)alkyl
  • Q 2 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl- (l- ⁇ C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl group within a R 2 group optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, trifluoromethoxy, carboxy, carbamoyl, (l-8C)alkyl, (l-6C)alkoxy
  • X 3 is a direct bond or is selected from O and N(R 7 ), wherein R 7 is hydrogen or (l-8C)alkyl, and R 6 is hydroxy-(l-6C)alkyl, (l-6C)alkoxy-(l-6C)alkyl, cyano-(l-6C)alkyl, amino-(l-6C)alkyl, (l-6C)alkylamino-(l-6C)alkyl and di-[(l-6C)alkyl]amino-(l-6C)alkyl, or from a group of the formula :
  • X 4 is a direct bond or is selected from O, CO and N(R 8 ), wherein R 8 is hydrogen or (l-8C)alkyl
  • Q 3 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and the Q 3 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, cyano, hydroxy, (l-8C)alkyl, (l-6C)alkoxy, (l-6C)alkylthio, (l-6C)alkylsulphinyl, (l-6C)alkylsulphonyl and (2-6C)alkanoyl, and wherein any heterocyclyl group within the R 2 group optionally
  • the R 2 group is selected from (l-6C)alkoxy, (l-6C)alkylsulphonyl, (l- ⁇ C)alkylamino, di-[(l-6C)alkyl]amino, N-(l-6C)alkylcarbamoyl, (2-6C)alkanoylamino, (l-6C)alkanesulphonylamino and N-(I -6C)alkylsulphamoyl, or from a group of the formula :
  • X 1 is selected from O, SO 2 , NH, CONH, NHCO, SO 2 NH and NHSO 2
  • Q 1 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any CH 2 or CH 3 group within a R 2 group optionally bears on each said CH 2 or CH 3 group one or more halogeno or (l-8C)alkyl substituents and/or a substituent selected from hydroxy, (l-6C)alkoxy, (l-6C)alkylamino and di-[(l-6C)alkyl]amino, or from a group of the formula :
  • X 2 is a direct bond or is selected from O and NH
  • Q 2 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl group within a R 2 group optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, trifluoromethoxy, carboxy, carbamoyl, (l-8C)alkyl, (l- ⁇ C)alkoxy, (l-6C)alky Sulphonyl, (l-6C)alkylamino, di- [( 1
  • X 3 is O and R 6 is hydroxy-(l-6C)alkyl, (l-6C)alkoxy-(l-6C)alkyl, cyano-(l-6C)alkyl, (l-6C)alkylamino-(l-6C)alkyl and di-[(l-6C)alkyl]amino-(l-6C)alkyl, or from a group of the formula :
  • X 4 is a direct bond or O
  • Q 3 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl
  • the Q 3 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, cyano, hydroxy, (l-8C)alkyl, (l- ⁇ C)alkoxy, (l- ⁇ C)alkylthio, (l-6C)alkylsul ⁇ hinyl, (l- ⁇ C)alkylsul ⁇ honyl and (2-6C)alkanoyl
  • the R 2 group is selected from (l-6C)alkylamino, di-[(l-6C)alkyl] amino, (2-6
  • X 1 is selected from NH, NHCO and NHSO 2
  • Q 1 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any CH 2 or CH 3 group within a R 2 group optionally bears on each said CH 2 or CH 3 group one or more halogeno or (l-8C)alkyl substituents and/or a substituent selected from hydroxy, (l-6C)alkoxy, (l- ⁇ C)alkylamino and di-[(l-6C)alkyl]amino, or from a group of the formula :
  • X 2 is a direct bond or is selected from O and NH
  • Q 2 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl group within a R 2 group optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, trifluoromethoxy, carboxy, carbamoyl, (l-8C)alkyl, (l- ⁇ C)alkoxy, (l- ⁇ C)alkylsulphonyl, (l-6C)alkylamino, di-[
  • X 3 is O and R 6 is hydroxy-(l-6C)alkyl, (l-6C)alkoxy-(l-6C)alkyl, cyano-(l-6C)alkyl, (l-6C)alkylamino-(l-6C)alkyl and di-[(l-6C)alkyl]amino-(l-6C)alkyl, or from a group of the formula :
  • R 2 is a (l- ⁇ C)alkylamino group or a group of the formula :
  • Q 1 is aryl-(l-6C)alkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl-(l-6C)alkyl or heterocyclyl-( 1 -6C)alkyl, and wherein any aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl group within a R 2 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, (l-8C)alkyl, (l-6C)alkoxy, (l-6C)alkylsulphonyl, (l- ⁇ C)alkylamino, di-[(l-6C)alkyl]amino, (2-6C)alkanoyl and (2-6C)alkanoylamino, or from a group of the formula : -O-R 6 wherein R 6 is hydroxy-(l-6C)alkyl, 3-(
  • X 4 is a direct bond or O
  • Q 3 is aryl, aryl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl
  • the Q 3 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, cyano, (l-8C)alkyl, (l-6C)alkoxy, (l-6C)alkylsulphonyl and (2-6C)alkanoyl
  • R is a (l-6C)alkanesulphonylamino group or a group of the formula :
  • Q 1 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl group within a R 2 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, carboxy, (l-8C)alkyl, (l- ⁇ C)alkoxy, (l- ⁇ C)alkylsulphonyl, (l-6C)alkylamino, di-[(l-6C)alkyl]amino, (l- ⁇ C)alkoxycarbonyl, (2-6C)alkanoy
  • R 6 is hydroxy-(l-6C)alkyl, (l-6C)alkoxy-(l-6C)alkyl, cyano-(l-6C)alkyl, (l-6C)alkylamino-(l-6C)alkyl and di-[(l-6C)alkyl]amino-(l-6C)alkyl, or from a group of the formula :
  • X 4 is a direct bond or O
  • Q 3 is aryl, aryl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl
  • the Q 3 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, cyano, (l-8C)alkyl, (l-6C)alkoxy, (l- ⁇ C)alkylsulphonyl and (2-6C)alkanoyl
  • R 2 is methanesulphonylamino, ethanesulphonylamino, propanesulphonylamino, 2,2-difluoroethanesulphonylamino, 2,2,2-trifluoroethanesulphonylamino, 2-chloroethanesulphonylamino, 3 -chloropropanesul
  • R is a group of the formula :
  • R 4 is hydrogen, methyl, ethyl or acetyl
  • Q 1 is phenyl, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl or pyridazinyl, each of which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, amino, nitro, trifluo
  • R 2 is methanesulphonylamino, ethanesulphonylamino or propanesulphonylamino, or a group of the formula :
  • Q 1 is phenyl, benzyl, cyclopropyl, cyclopropylmethyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 4-imidazolyl, 4-pyrazolyl, 5-oxazolyl, 4-isoxazolyl, 5-thiazolyl, 4-isothiazolyl or 3 -pyridyl, each of which optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, amino, carboxy, methyl, ethyl, methoxy, ethoxy, methylsulphonyl, methylamino, dimethylamino, methoxycarbonyl, acetyl, acetamido and morpholino;
  • R 2 is amino, methylamino, ethylamino, propylamino, dimethylamino, diethylamino, 2-hydroxyethylamino, 3-hydroxypropylamino, 3-methylaminopropylamino, 3-dimethylaminopropylamino, 3-ethylaminopropylamino or 3-diethylaminopropylamino, or R 2 is a group of the formula : wherein R 4 is hydrogen, methyl or ethyl, and Q 1 is benzyl, pyrrolylmethyl, furylmethyl, thienylmethyl, imidazolylmethyl, pyrazolylmethyl, oxazolylmethyl, isoxazolylmethyl, thiazolylmethyl, isothiazolylmethyl, oxadiazolylmethyl, thiadiazolylmethyl, triazolylmethyl, pyridylmethyl, pyrazinylmethyl, pyrimidinylmethyl or
  • n 1 or 2 and each R 3 group that is present, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, hydroxy, (l-6C)alkyl, (2-6C)alkenyl,
  • (aa) n is 1 and the R 3 group is selected from halogeno, trifluoromethyl, cyano, hydroxy,
  • n 1 and the R 3 group is selected from halogeno, (l-6C)alkyl and (l-6C)alkoxy;
  • n 1 and the R 3 group is selected from fluoro, chloro, bromo, methyl, ethyl and methoxy;
  • n 0 or n is 1 and the R 3 group is selected from fluoro, chloro, bromo, trifluoromethyl, cyano, methyl, ethyl, methoxy, ethoxy and methylsulphonyl;
  • n 0 or n is 1 and the R 3 group is selected from fluoro, chloro, bromo, methyl, ethyl and methoxy;
  • n 0 or n is 1 and the R 3 group is selected from methyl and ethyl;
  • (gg) n is 1 and the R 3 group is selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, (l-8C)alkyl, (l-6C)alkoxy, (l- ⁇ C)alkylthio, (l-6C)alkylsulphinyl,
  • X 5 is selected from O, S, SO, SO 2 , N(R 9 ), CON(R 9 ), N(R 9 )CO, N(R 9 )CON(R 9 ), SO 2 N(R 9 ) and N(R 9 )SO 2 , wherein each R 9 group is hydrogen, (l-8C)alkyl or (2-6C)alkanoyl, and Q 4 is aryl, aryl-(l-6C)alkyl, aryloxy-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl- (l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any CH, CH 2 or CH 3 group within a R 3 group optionally bears on each said CH, CH 2 or CH 3 group one or more halogeno or (l-SC)alkyl substitu
  • Q 6 -X 9 - wherein X 9 is a direct bond or is selected from O, CO and N(R 15 ), wherein R 15 is hydrogen or (l-8C)alkyl, and Q 6 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and the Q 6 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, cyano, hydroxy, (l-8C)alkyl, (l-6C)alkoxy, (l-6C)alkylthio, (l- ⁇ C)alkylsulphinyl, (l-6C)alkylsulphonyl and (2-6C)alkanoyl, and wherein any heterocyclyl group within the R 3 group
  • n 1 and the R 3 group is selected from (l- ⁇ C)alkoxy, (l- ⁇ C)alkylsulphonyl, (l-6C)alkylamino, di-[(l-6C)alkyl] amino, TV-(I -6C)alkylcarbamoyl, (2-6C)alkanoylamino, (l-6C)alkanesulphonylamino and TV-(I -6C)alkylsulphamoyl, or from a group of the formula :
  • Q 4 -X 5 - wherein X 5 is selected from O, SO 2 , NH, CONH, NHCO, SO 2 NH and NHSO 2 , and Q 4 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any CH 2 or CH 3 group within a R 3 group optionally bears on each said CH 2 or CH 3 group one or more halogeno or (l-8C)alkyl substituents and/or a substituent selected from hydroxy, (l-6C)alkoxy, (l-6C)alkylamino and di-[(l-6C)alkyl]amino, or from a group of the formula :
  • X 7 is a direct bond or is selected from O and NH
  • Q 5 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl group within a R 3 group optionally bears 1 , 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, trifluoromethoxy, carboxy, carbamoyl, (l-8C)alkyl, (l-6C)alkoxy, (l- ⁇ C)alkylsulphonyl, (l-6C)alkylamino, di-
  • R l3 -X 8 - wherein X 8 is O and R 13 is hydroxy-(l-6C)alkyl, (l-6C)alkoxy-(l-6C)alkyl, cyano-(l-6C)alkyl, (l-6C)alkylamino-(l-6C)alkyl and di-[(l-6C)alkyl]amino-(l-6C)alkyl, or from a group of the formula :
  • Q 6 -X 9 - wherein X 9 is a direct bond or O, and Q 6 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and the Q 3 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, cyano, hydroxy, (l-8C)alkyl, (l- ⁇ C)alkoxy, (l-6C)alkylthio, (l-6C)alkylsulphinyl, (l- ⁇ C)alkylsulphonyl and (2-6C)alkanoyl; (ii) n is 1 and the R 3 group is selected from (l-6C)alkylamino, di-[(l-6C)alkyl] amino
  • Q 4 -X 5 - wherein X 5 is selected from NH, NHCO and NHSO 2 , and Q 4 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any CH 2 or CH 3 group within a R 3 group optionally bears on each said CH 2 or CH 3 group one or more halogeno or (l-8C)alkyl substituents and/or a substituent selected from hydroxy, (l-6C)alkoxy, (l- ⁇ C)alkylamino and di-[(l-6C)alkyl]amino, or from a group of the formula :
  • Q 5 -X 7 - wherein X 7 is a direct bond or is selected from O and NH, and Q 5 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl group within a R 3 group optionally bears 1 , 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, trifluoromethoxy, carboxy, carbamoyl, (l-8C)alkyl, (l-6C)alkoxy, (l-6C)alkylsulphonyl, (l-6C)alkylamino, di-
  • R 13 -X 8 - wherein X 8 is O and R 13 is hydroxy-(l-6C)alkyl, (l-6C)alkoxy-(l-6C)alkyl, cyano-(l-6C)alkyl, (l-6C)alkylammo-(l-6C)alkyl and di-[(l-6C)alkyl]amino-(l-6C)alkyl, or from a group of the formula :
  • Q 6 -X 9 - wherein X 9 is a direct bond or O, and Q 6 is aryl, aryl-(l-6C)alkyl (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and the Q 6 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, cyano, hydroxy, (l-8C)alkyl, (l- ⁇ C)alkoxy, (l-6C)alkylthio, (l- ⁇ C)alkylsulphinyl, (l-6C)alkylsulphonyl and (2-6C)alkanoyl; (jj) n is 1 and the R 3 group is selected from amino, iV-(l-6C)alkyIamino iV,N-di
  • X 5 is N(R 9 ), wherein R 9 is hydrogen or (l-6C)alkyl
  • Q 4 is aryl, aryl-(l-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl, heteroaryl-(l-6C)alkyl, heterocyclyl or heterocyclyl-(l-6C)alkyl, and wherein any aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl group within a R 3 group optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, (l-6C)alkyl, (l-6C)alkoxy, (l-6C)alkylsulphonyl, (l-6C)alkylamino, di-[(l-6C)alkyl]amino
  • Q 4 is aryl-(l-6C)alkyl, (3-8C)cycloalkyl-(l-6C)alkyl or heteroaryl-(l-6C)alkyl, and wherein any aryl, (3-8C)cycloalkyl or heteroaryl group within a R 3 group optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, (l- ⁇ C)alkyl and (l-6C)alkoxy; (11) n is 1 and R 3 is amino, iV-methylamino, iV-ethylaniino, iV-propylamino, iV-isopropylamino, anilino, iV-benzylamino or iV-cyclopropylamino, and each of the three last named groups optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chlor
  • a particular compound of the invention is an indole derivative of the Formula II
  • R2 II wherein :- m is 0 or m is 1 and the R 1 group is selected from fluoro, chloro, bromo, trifluoromethyl, cyano, methyl, ethyl, methoxy, ethoxy and methylsulphonyl;
  • R 2 is methanesulphonylamino, ethanesulphonylamino, propanesulphonylamino, 2,2-difluoroethanesulphonylamino, 2,2,2-trifluoroethanesulphonylamino, 2-chloroethanesulphonylaniino, 3 -chloropropanesulphonylamino, 2-hydroxyethanesulphonylamino, 3-hydroxypropanesulphonylamino, 3 -methylaminopropanesulphonylamino, 3 -dimethylaminopropanesulphonylamino, 3-ethylaminopropanesulphonylamino, 3-diethylaminopropanesulphonylamino, S-cyclopentylaminopropanesulphonylamino, S-cyclohexylaminopropanesulphonylamino, 3-(cyclopentylmethylamino)propanesulphon
  • R 2 is a group of the formula :
  • R 4 is hydrogen, methyl, ethyl or acetyl
  • Q 1 is phenyl, benzyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl or pyridazinyl, each of which optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, amino, nitro, trifluorome
  • Gi is CH or ⁇ ; and n is O or n is 1 and the R 3 group is selected from fluoro, chloro, bromo, trifluoromethyl, cyano, amino, methyl, ethyl, methoxy, ethoxy, methylamino and methylsulphonyl; or a pharmaceutically-acceptable salt thereof.
  • a further particular compound of the invention is an indole derivative of the Formula II wherein :- m is 0 or m is 1 and the R 1 group is selected from fluoro, chloro, bromo, methyl, ethyl and methoxy;
  • R 2 is methanesulphonylamino, ethanesulphonylamino, 2,2,2-ti ⁇ fluoroethanesulphonylamino or propanesulphonylamino, or a group of the formula :
  • Q 1 is phenyl, benzyl, cyclopropyl, cyclopropylmethyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 4-imidazolyl, 4-pyrazolyl, 5-oxazolyl, 4-isoxazolyl, 5-thiazolyl, 4-isothiazolyl or 3-pyridyl, each of which optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, amino, carboxy, methyl, ethyl, methoxy, ethoxy, methylsulphonyl, methylamino, dimethylamino, methoxycarbonyl, acetyl and acetamido;
  • G 1 is CH or N; and n is O or n is 1 and the R 3 group is selected from fluoro, chloro, bromo, methyl, ethyl and methoxy; or a pharmaceutically-acceptable salt thereof.
  • a further particular compound of the invention is an indole derivative of the Formula II wherein :- m is O or m is 1 and the R 1 group is selected from chloro and methyl;
  • R is methanesulphonylamino or 2,2,2-trifluoroethanesulphonylamino, or a group of the formula :
  • Q 1 is phenyl or 5-thiazolyl, each of which optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, methyl and methoxy;
  • Gi is CH or N; and n is O or n is 1 and the R 3 group is methyl; or a pharmaceutically-acceptable salt thereof.
  • a further particular compound of the invention is an indole derivative of the Formula II
  • R2 II wherein :- m is 0 or m is 1 and the R 1 group is selected from fluoro, chloro, bromo, trifluoromethyl, cyano, methyl, ethyl, methoxy, ethoxy and methylsulphonyl;
  • R 2 is amino, methylamino, ethylamino, propylamino, dimethylamino, diethylamino, 2-hydroxyethylamino, 3-hydroxypropylamino, 3-methylaminopropylamino, 3-dimethylaminopropylamino, 3-ethylaminopropylamino or 3-diethylaminopropylamino, or R 2 is a group of the formula : wherein R 4 is hydrogen, methyl or ethyl, and Q 1 is benzyl, pyrrolylmethyl, furylmethyl, thienylmethyl, imidazolylmethyl, pyrazolylmethyl, oxazolylmethyl, isoxazolylmethyl, thiazolylmethyl, isothiazolylmethyl, oxadiazolylmethyl, thiadiazolylmethyl, triazolylmethyl, pyridylmethyl, pyrazinylmethyl, pyrimidinylmethyl or pyr
  • G 1 is CH or N; and n is 0 or n is 1 and the R 3 group is selected from fluoro, chloro, bromo, trifluoromethyl, cyano, amino, methyl, ethyl, methoxy, ethoxy, methylamino and methylsulphonyl; or a pharmaceutically-acceptable salt thereof.
  • a further particular compound of the invention is an indole derivative of the Formula II wherein :- m is 0 or m is 1 and the R 1 group is selected from fluoro, chloro, bromo, methyl, ethyl and methoxy;
  • R 2 is a group of the formula :
  • Q 1 is benzyl, 2-pyrrolylmethyl, 3-pyrrolylmethyl, 2-furylmethyl, 3-furylmethyl, 2-thienylmethyl, 3-thienylmethyl, 4-imidazolylmethyl, 4-pyrazolylmethyl, 5-oxazolylmethyl, 4-isoxazolylmethyl, 5-thiazolylmethyl, 4-isothiazolylmethyl, l,2,3-triazol-4-ylmethyl and 3-pyridylmethyl, each of which optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, amino, carboxy, methyl, ethyl, methoxy, ethoxy, methylsulphonyl, methylamino, dimethylamino, methoxycarbonyl, acetyl and acetamido;
  • G 1 is CH or N; and n is 0 or n is 1 and the R 3 group is selected from fluoro, chloro, bromo, methyl, ethyl and methoxy; or a pharmaceutically-acceptable salt thereof.
  • a further particular compound of the invention is an indole derivative of the Formula II wherein :- m is 0 or m is 1 and the R 1 group is selected from chloro and methyl;
  • R 2 is a group of the formula :
  • Q 1 is benzyl or 4-pyrazolylmethyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from fluoro, chloro, methyl and ethyl;
  • G 1 is CH or N; and n is 0 or n is 1 and the R 3 group is methyl; or a pharmaceutically-acceptable salt thereof.
  • a particular compound of the invention is, for example, an indole derivative of the Formula I that is disclosed hereinafter amongst the Examples.
  • a particular compound of the invention is an indole derivative of the Formula I that is disclosed as Example 1, or as Compound No. 1 within Example 2, or as Example 3, or as Compound No. 1 within Example 4, or as Example 7; or a pharmaceutically- acceptable salt thereof.
  • An indole derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes, when used to prepare an indole derivative of the Formula I are provided as a further feature of the invention and are illustrated by the following representative Process Variants in which, unless otherwise stated, each of Ring A, m, R 1 , R 2 , G 1 , n and R 3 have any of the meanings defined hereinbefore.
  • Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described in conjunction with the following representative Process Variants and within the accompanying Examples. Alternatively, necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.
  • L is a displaceable group and G 1 , n and R 3 have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an organoboron reagent of the Formula XIII
  • each of L 1 and L 2 which may be the same or different, is a suitable ligand and Ring A, m, R 1 and R 2 have any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed.
  • a suitable displaceable group L is, for example, a halogeno, alkoxy, aryloxy or sulphonyloxy group, for example a chloro, bromo, iodo, methoxy, phenoxy, pentafluorophenoxy, methanesulphonyloxy or toluene-4-sulphonyloxy group.
  • the displaceable group is an iodo group.
  • a suitable value for the ligands L 1 and L 2 which are present on the boron atom of the organoboron reagent include, for example, a hydroxy, (l-4C)alkoxy or (l-6C)alkyl ligand, for example a hydroxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methyl, ethyl, propyl, isopropyl or butyl ligand.
  • the ligands L 1 and L 2 may be linked such that, together with the boron atom to which they are attached, they form a ring.
  • L 1 and L 2 together may define an oxy-(2-4C)alkylene-oxy group, for example an oxyethyleneoxy, oxytrimethyleneoxy group or -O-C(CH 3 ) 2 C(CH 3 ) 2 -O- group such that, together with the boron atom to which they are attached, they form a cyclic boronic acid ester group.
  • Particularly suitable organoboron reagents include, for example, compounds wherein each of L 1 and L 2 is a hydroxy, a isopropoxy or an ethyl group or L 1 and L 2 together define a group of formula -O-C(CH 3 ) 2 C(CH 3 ) 2 -O-.
  • a suitable catalyst for the reaction includes, for example, a metallic catalyst such as a palladium(O), palladium(II), nickel(O) or nickel(II) catalyst, for example tetrakis(triphenylphosphine)palladium(0), palladium(II) chloride, palladium(II) bromide, bis(triphenylphosphine)palladium(II) chloride, tetrakis(triphenylphosphine)nickel(0), nickel(II) chloride, nickel(II) bromide, bis(triphenylphosphine)nickel(II) chloride or [l,r-bis(diphenylphosphino)ferrocene]dichloropalladium(II).
  • a metallic catalyst such as a palladium(O), palladium(II), nickel(O) or nickel(II) catalyst, for example tetrakis(triphenylphosphine)palladium
  • a free radical initiator may conveniently be added, for example an azo compound such as azo(bisisobutyronitrile).
  • the reaction may be carried out in the presence of a suitable base such as an alkali or alkaline earth metal carbonate or hydroxide, for example sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, calcium carbonate, caesium carbonate, sodium hydroxide or potassium hydroxide, or, for example, an alkali metal alkoxide, for example sodium tert-butoxide, or, for example, an alkali metal amide, for example sodium hexamethyldisilazane, or, for example, an alkali metal hydride, for example sodium hydride.
  • a suitable base such as an alkali or alkaline earth metal carbonate or hydroxide, for example sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, calcium carbonate, caesium carbonate, sodium hydroxide or potassium hydroxide, or, for example, an
  • the reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an ether such as tetrahydrofuran, 1,4-dioxan or 1,2-dimethoxyethane, an aromatic solvent such as benzene, toluene or xylene, or an alcohol such as methanol or ethanol, and the reaction is conveniently carried out at a temperature in the range, for example, 10 to 25O 0 C, preferably in the range 40 to 120 0 C.
  • a suitable inert solvent or diluent for example an ether such as tetrahydrofuran, 1,4-dioxan or 1,2-dimethoxyethane, an aromatic solvent such as benzene, toluene or xylene, or an alcohol such as methanol or ethanol
  • Heteroaryl-boron reagents of the Formula XIII may be obtained by standard procedures of organic chemistry which are within the ordinary skill of an organic chemist.
  • a heteroaryl-metal reagent where the metal is, for example, lithium or the magnesium halide portion of a Grignard reagent, may be reacted with an organoboron compound of the formula L-B(L 1 XL 2 ) wherein L is a displaceable group as defined hereinbefore.
  • the compound of the formula L-B(L 1 XL 2 ) is, for example, boric acid or a tri-(l-4C)alkyl borate such as tri-isopropyl borate.
  • a heteroaryl-boron reagent of the Formula XIII may be replaced with an organometallic compound of the formula heteroaryl-M wherein M is a metal atom or a metallic group (that is a metal atom bearing suitable ligands).
  • M is a metal atom or a metallic group (that is a metal atom bearing suitable ligands).
  • Suitable values for the metal atom include, for example, lithium and copper.
  • Suitable values for the metallic group include, for example, groups which contain a tin, silicon, zirconium, aluminium, magnesium, mercury or zinc atom.
  • Suitable ligands within such a metallic group include, for example, hydroxy groups, (l-6C)alkyl groups such as methyl, ethyl, propyl, isopropyl and butyl groups, halogeno groups such as chloro, bromo and iodo groups, and (l-6C)alkoxy groups such as methoxy, ethoxy, propoxy, isopropoxy and butoxy groups.
  • a particular organometallic compound of the formula heteroaryl-M is, for example, an organotin compound such as a compound of the formula heteroaryl- SnBu 3 , an organosilicon compound such as a compound of the formula heteroaryl-Si(Me)F 2 , an organozirconium compound such as a compound of the formula heteroary 1-ZrCl 3 , an organoaluminium compound such as a compound of the formula heteroaryl- AlEt 2 , an organomagnesium compound such as a compound of the formula heteroaryl-MgBr, an organomercury compound such as a compound of the formula heteroaryl-HgBr, or an organozinc compound such as a compound of the formula heteroaryl-ZnBr.
  • an organotin compound such as a compound of the formula heteroaryl- SnBu 3
  • an organosilicon compound such as a compound of the formula heteroaryl-Si(Me)F 2
  • Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question and may be introduced by conventional methods. Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
  • protecting groups are given below for the sake of convenience, in which "lower”, as in, for example, lower alkyl, signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned are, of course, within the scope of the invention.
  • a carboxy protecting group may be the residue of an ester-forming aliphatic or arylaliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms).
  • carboxy protecting groups include straight or branched chain (l-12C)alkyl groups (for example isopropyl, and tert-butyl); lower alkoxy- lower alkyl groups (for example methoxymethyl, ethoxymethyl and isobutoxymethyl); lower acyloxy-lower alkyl groups, (for example acetoxymethyl, propionyloxymethyl, butyryloxymethyl and pivaloyloxymethyl); lower alkoxycarbonyloxy-lower alkyl groups (for example 1-methoxycarbonyloxy ethyl and 1-ethoxycarbonyloxy ethyl); aryl-lower alkyl groups (for example benzyl, 4-methoxybenzyl, 2-nitrobenzyl, 4-nitrobenzyl
  • hydroxy protecting groups include lower alkyl groups (for example tert-buty ⁇ ), lower alkenyl groups (for example allyl); lower alkanoyl groups (for example acetyl); lower alkoxycarbonyl groups (for example tert-butoxycarbonyl); lower alkenyloxycarbonyl groups (for example allyloxycarbonyl); aryl-lower alkoxycarbonyl groups (for example benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl); tri(lower alkyl)silyl (for example trimethylsilyl and fert-butyldimethylsilyl) and aryl-lower alkyl (for example benzyl) groups.
  • lower alkyl groups for example tert-buty ⁇
  • lower alkenyl groups for example allyl
  • lower alkanoyl groups for example acetyl
  • amino protecting groups include formyl, aryl-lower alkyl groups (for example benzyl and substituted benzyl, 4-methoxybenzyl, 2-nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl); di-4-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl (for example t ⁇ rt-butoxycarbonyl); lower alkenyloxycarbonyl (for example allyloxycarbonyl); aryl-lower alkoxycarbonyl groups (for example benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl and 4-nitrobenzyloxycarbonyl); trialkylsilyl (for example trimethylsilyl and fert-butyldimethylsilyl); alkylidene (for example methylidene) and benzylidene and substituted benzylidene groups.
  • aryl-lower alkyl groups for example
  • Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base-, metal- or enzymically-catalysed hydrolysis for groups such as 2-nitrobenzyloxycarbonyl, hydrogenation for groups such as benzyl and photolytically for groups such as 2-nitrobenzyloxycarbonyl.
  • Indole starting materials of the Formula XII may be obtained by conventional procedures such as those disclosed in the Examples that are set out hereinafter.
  • L is a displaceable group as defined hereinbefore and Ring A, m, R 1 and R 2 have any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed.
  • a suitable transition metal catalyst for the reaction is, for example, a catalyst such as a palladium(O), palladium(II), nickel(O) or nickel(II) catalyst, for example tetrakis(triphenylphosphine)palladium(0), palladium(II) chloride, palladium(II) bromide, bis(triphenylphosphine)palladiurn(II) chloride, tris(dibenzylideneacetone)dipalladium(0) tetrakis(triphenylphosphine)nickel(0), nickel(II) chloride, nickel(II) bromide or bis(triphenylphosphine)nickel(II) chloride.
  • the transition metal catalyst is a palladium catalyst, for example palladium(II) acetate.
  • a phosphine ligand for the transition metal is present, for example triphenylphosphine, tributylphosphine or 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene. More conveniently, the phosphine ligand is tri-te ⁇ -t-butylphosphine.
  • a suitable base for the reaction is an alkali or alkaline earth metal carbonate or hydroxide, for example sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, calcium carbonate, caesium carbonate, sodium hydroxide or potassium hydroxide.
  • the reaction is carried out in the presence of caesium fluoride.
  • the process may be carried out in an organic solvent such as DMSO and the reaction temperature may be from about 60°C to 200 0 C, conveniently at about 130°C to 15O 0 C.
  • organic solvent such as DMSO
  • Indole starting materials of the Formula XIV may be obtained by conventional procedures such as those disclosed in the scientific literature or within the Examples that are set out hereinafter.
  • compounds of the Formula XV may be obtained by conventional procedures such as those disclosed in the scientific literature or within the Examples that are set out hereinafter.
  • Ring A, m, R 1 , Gj, n and R 3 have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with a (l-6C)alkanesulphonic acid, or a reactive derivative thereof, whereafter any protecting group that is present is removed by conventional means.
  • a suitable base for this alkanesulphonylation reaction is, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, iV-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or, for example, an alkali or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide, or, for example, an alkali metal amide, for example sodium hexamethyldisilazane, or, for example, an alkali metal hydride, for example sodium hydride.
  • an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, iV-methylmorpholine or diazabicyclo[5.4.0]
  • a suitable reactive derivative of a (l-6C)alkanesulphonic acid is, for example, an alkanesulphonyl halide, for example an alkanesulphonyl chloride formed by the reaction of the sulphonic acid with an inorganic acid chloride, for example thionyl chloride or the product of the reaction of the sulphonic acid with a carbodiimide such as dicyclohexylcarbodiimide.
  • the reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an alcohol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, an aromatic solvent such as toluene.
  • a suitable inert solvent or diluent for example an alcohol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, an aromatic solvent such as toluene.
  • a dipolar aprotic solvent such as ⁇ iV-dimethylformamide, N,J
  • Indole starting materials of the Formula XVI may be obtained conventionally, for example by way of Process Variants (a) or (b) as described hereinbefore and/or using procedures such as those disclosed within the Examples that are set out hereinafter, (d) For the production of those compounds of the Formula I wherein R 2 is a group of the formula :-
  • X 1 is a N(R 4 )SO 2 group and Q 1 has any of the meanings defined hereinbefore, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of a compound of the Formula XVII wherein Ring A, m, R 1 , G 1 , n, R 3 and R 4 have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with a sulphonic acid of the formula :-
  • HO -SO 2 -Q 1 is, for example, a sulphonyl halide, for example a sulphonyl chloride formed by the reaction of the sulphonic acid with an inorganic acid chloride, for example thionyl chloride or the product of the reaction of the sulphonic acid with a carbodiimide such as dicyclohexylcarbodiimide.
  • a sulphonyl halide for example a sulphonyl chloride formed by the reaction of the sulphonic acid with an inorganic acid chloride, for example thionyl chloride or the product of the reaction of the sulphonic acid with a carbodiimide such as dicyclohexylcarbodiimide.
  • the reaction is conveniently carried out in the presence of a suitable inert solvent or diluent as defined hereinbefore.
  • the reaction is conveniently carried out at a temperature in the range, for example, O to 120°C, preferably at or near ambient temperature.
  • Indole starting materials of the Formula XVII may be obtained conventionally, for example by way of Process Variants (a) or (b) as described hereinbefore and/or using procedures such as those disclosed within the Examples that are set out hereinafter, (e) For the production of those compounds of the Formula I wherein R 2 is a group of the formula :-
  • X 1 is a SO 2 N(R 4 ) group and Q 1 has any of the meanings defined hereinbefore, the reaction, conveniently in the presence of a suitable base as defined hereinbefore, of a sulphonic acid of the Formula XVIII XVIII or a reactive derivative thereof as defined hereinbefore, wherein Ring A, m, R 1 , G 1 , n and R 3 have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an amine of the formula :-
  • R 4 NH-Q 1 wherein R 4 and Q 1 have any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed.
  • the reaction is conveniently carried out in the presence of a suitable inert solvent or diluent as defined hereinbefore.
  • the reaction is conveniently carried out at a temperature in the range, for example, O to 120°C, preferably at or near ambient temperature.
  • Indole starting materials of the Formula XVIII may be obtained conventionally, for example by way of Process Variants (a) or (b) as described hereinbefore and/or using procedures that are analogous to those disclosed within the Examples that are set out hereinafter.
  • Ring A, m, R 1 , Gi, n and R 3 have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with a (2-6C)alkanoic acid, or a reactive derivative thereof, whereafter any protecting group that is present is removed.
  • a suitable reactive derivative of a (2-6C)alkanoic acid is, for example, an acyl halide, for example an acyl chloride formed by the reaction of the acid with an inorganic acid chloride, for example thionyl chloride; a mixed anhydride, for example an anhydride formed by the reaction of the acid with a chloroformate such as isobutyl chloroformate; an active ester, for example an ester formed by the reaction of the acid with a phenol such as pentafluorophenol, with an ester such as pentafluorophenyl trifluoroacetate or with an alcohol such as methanol, ethanol, isopropanol, butanol or N-hydroxybenzotriazole; an acyl azide, for example an azide formed by the reaction of the acid with an azide such as diphenylphosphoryl azide; an acyl cyanide, for example a cyanide formed by the reaction of an acid with a cyanide such as die
  • reaction is conveniently carried out in the presence of a suitable inert solvent or diluent as defined hereibefore.
  • the reaction is conveniently carried out at a temperature in the range, for example, 0 to 120 0 C, preferably at or near ambient temperature, (g)
  • a suitable inert solvent or diluent as defined hereibefore.
  • the reaction is conveniently carried out at a temperature in the range, for example, 0 to 120 0 C, preferably at or near ambient temperature, (g)
  • R 2 is a group of the formula :-
  • Ring A, m, R 1 , Gi, n, R 3 and R 4 have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with a carboxylic acid of the formula :-
  • HO 2 C-Q 1 is, for example, an acyl chloride formed by the reaction of the acid with an inorganic acid chloride, for example thionyl chloride; or the product of the reaction of the acid with a carbodiimide such as dicyclohexylcarbodiimide or with a uronium compound such as 2-(7-azabenzotriazol- 1 -yl)- 1 , 1 ,3 ,3 -tetramethyluronium hexafluorophosphate(V).
  • a carbodiimide such as dicyclohexylcarbodiimide
  • a uronium compound such as 2-(7-azabenzotriazol- 1 -yl)- 1 , 1 ,3 ,3 -tetramethyluronium hexafluorophosphate(V).
  • reaction is conveniently carried out in the presence of a suitable inert solvent or diluent as defined hereinbefore.
  • the reaction is conveniently carried out at a temperature in the range, for example, 0 to 12O 0 C, preferably at or near ambient temperature, (h)
  • a suitable inert solvent or diluent as defined hereinbefore.
  • the reaction is conveniently carried out at a temperature in the range, for example, 0 to 12O 0 C, preferably at or near ambient temperature, (h)
  • R 2 is a group of the formula :-
  • Ring A, m, R 1 , G 1 , n and R 3 have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with an amine of the formula :-
  • R 4 NH-Q 1 wherein R 4 and Q 1 have any of the meanings defined hereinbefore except that any functional group is protected if necessary, whereafter any protecting group that is present is removed.
  • the reaction is conveniently carried out in the presence of a suitable inert solvent or diluent as defined hereinbefore.
  • the reaction is conveniently carried out at a temperature in the range, for example, 0 to 120°C, preferably at or near ambient temperature.
  • Indole starting materials of the Formula XIX may be obtained conventionally, for example by way of Process Variants (a) or (b) as described hereinbefore and/or using procedures that are analogous to those disclosed within the Examples that are set out hereinafter. (i) For the production of those compounds of the Formula I wherein R 2 is a group of the formula :-
  • X 1 is a N(R 4 ) group and Q 1 is a aryl-(l-6C)alkyl, aryloxy-(l-6C)alkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl-(l-6C)alkyl or heterocyclyl-(l-6C)alkyl group, the alkylation, conveniently in the presence of a suitable base as defined hereinbefore, of a compound of the Formula XVII
  • Ring A, m, R 1 , G 1 , n, R 3 and R 4 have any of the meanings defined hereinbefore except that any functional group is protected if necessary, with a compound of the formula :-
  • L has any of the meanings defined hereinbefore and Q 1 is a aryl-(l-6C)alkyl, aryloxy-(l-6C)alkyl, (3-8C)cycloalkyl-(l-6C)alkyl, heteroaryl-(l-6C)alkyl or heterocyclyl-(l-6C)alkyl group except that any functional group is protected if necessary, whereafter any protecting group that is present is removed.
  • the reaction is conveniently carried out in the presence of a suitable inert solvent or diluent as defined hereinbefore.
  • the reaction is conveniently carried out at a temperature in the range, for example, 0 to 150°C, preferably at or near 50°C.
  • Q 1 is a aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl group except that any functional group is protected if necessary, whereafter any protecting group that is present is removed.
  • the reaction is conveniently carried out using known procedures for the reductive amination of aldehydes, for example using a reducing agent such as sodium cyanoborohydride or polymer-bound sodium cyanoborohydride in the presence of a carboxylic acid such as acetic acid.
  • a reducing agent such as sodium cyanoborohydride or polymer-bound sodium cyanoborohydride
  • carboxylic acid such as acetic acid.
  • the reaction is conveniently carried out in the presence of a suitable inert solvent or diluent as defined hereinbefore and at a temperature in the range, for example, 0 to 100°C, conveniently at about ambient temperature.
  • Suitable reducing agents for the reductive amination reaction include, for example, a hydride reducting agent, for example an alkali metal aluminium hydride such as lithium aluminium hydride or, preferably, an alkali metal borohydride such as sodium borohydride, sodium triethylborohydride, sodium trimethoxyborohydride and sodium triacetoxyborohydride.
  • a hydride reducting agent for example an alkali metal aluminium hydride such as lithium aluminium hydride or, preferably, an alkali metal borohydride such as sodium borohydride, sodium triethylborohydride, sodium trimethoxyborohydride and sodium triacetoxyborohydride.
  • the reaction is conveniently performed in a suitable inert solvent or diluent, for example tetrahydrofuran and diethyl ether for the more powerful reducing agents such as lithium aluminium hydride, and, for example, methylene chloride or a protic solvent such as methanol and ethanol for the less powerful reducing agents such as sodium triacetoxyborohydride and sodium cyanoborohydride.
  • a suitable inert solvent or diluent for example tetrahydrofuran and diethyl ether for the more powerful reducing agents such as lithium aluminium hydride, and, for example, methylene chloride or a protic solvent such as methanol and ethanol for the less powerful reducing agents such as sodium triacetoxyborohydride and sodium cyanoborohydride.
  • the indole derivative of the Formula I may be obtained from the process variants described hereinbefore in the form of the free base or alternatively it may be obtained in the form of a salt with the acid of the formula H-L wherein L has the meaning defined hereinbefore.
  • the salt may be treated with a suitable base, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, iV-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or, for example, an alkali or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.
  • a suitable base for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine,
  • a pharmaceutically-acceptable salt of an indole derivative of the Formula I for example an acid-addition salt, it may be obtained by, for example, reaction of said thiazole derivative with a suitable acid using a conventional procedure.
  • an in vivo cleavable ester of an indole derivative of the Formula I may be obtained by, for example, reaction of a compound of the Formula I containing a carboxy group with a pharmaceutically-acceptable alcohol or by reaction of a compound of the Formula I containing a hydroxy group with a pharmaceutically-acceptable carboxylic acid.
  • an in vivo cleavable amide of an indole derivative of the Formula I may be obtained by, for example, reaction of a compound of the Formula I containing a carboxy group with a pharmaceutically-acceptable amine or by reaction of a compound of the Formula I containing an amino group with a pharmaceutically-acceptable carboxylic acid.
  • the following assays can be used to measure the effects of the compounds of the present invention as PB kinase inhibitors, as mTOR PI kinase-related kinase inhibitors, as inhibitors in vitro of the activation of PI3 kinase signalling pathways, as inhibitors in vitro of the proliferation of MDA-MB-468 human breast adenocarcinoma cells, and as inhibitors in vivo of the growth in nude mice of xenografts of MDA-MB-468 carcinoma tissue, (a) In Vitro PI3K Enzyme Assay
  • the assay used AlphaScreen technology (Gray et al, Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant Type I PI3K enzymes of the lipid PI(4,5)P2.
  • DNA fragments encoding human PI3K catalytic and regulatory subunits were isolated from cDNA libraries using standard molecular biology and PCR cloning techniques. The selected DNA fragments were used to generate baculovirus expression vectors.
  • full length DNA of each of the pi 10a, pi lO ⁇ and pi lO ⁇ Type Ia human PI3K pi 10 isoforms (EMBL Accession Nos. HSU79143, S67334, Y10055 for pi 10a, pi lO ⁇ and pi lO ⁇ respectively) were sub-cloned into apDESTIO vector (Invitrogen Limited, Fountain Drive, Paisley, UK).
  • the vector is a Gateway-adapted version of Fastbacl containing a 6-His epitope tag.
  • Type Ib human PI3K pi lO ⁇ isoform corresponding to amino acid residues 144-1102 (EMBL Accession No. X8336A) and the full length human p85 ⁇ regulatory subunit (EMBL Accession No. HSP13KIN) were also sub-cloned into pFastBacl vector containing a 6-His epitope tag.
  • the Type Ia pi 10 constructs were co-expressed with the p85 ⁇ regulatory subunit.
  • expressed proteins were purified using the His epitope tag using standard purification techniques.
  • Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ⁇ l) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one, Brunei Way, Stonehouse, Gloucestershire, UK Catalogue No. 784075). A mixture of each selected recombinant purified PI3K enzyme (15 ng), DiC8-PI(4,5)P2 substrate (40 ⁇ M; Cell Signals Inc., Kinnear Road, Columbus, USA, Catalogue No.
  • LV low volume white polystyrene plate
  • adenosine triphosphate (ATP; 4 ⁇ M) and a buffer solution [comprising Tris-HCl pH7.6 buffer (40 mM, 10 ⁇ l), 3-[(3-cholamidopro ⁇ yl)dimethylamrnonio]- 1-pro ⁇ anesulphonate (CHAPS; 0.04%), dithiothreitol (DTT; 2 mM) and magnesium chloride (10 mM)] was agitated at room temperature for 20 minutes.
  • Tris-HCl pH7.6 buffer 40 mM, 10 ⁇ l
  • CHAT 3-[(3-cholamidopro ⁇ yl)dimethylamrnonio]- 1-pro ⁇ anesulphonate
  • DTT dithiothreitol
  • magnesium chloride 10 mM
  • Control wells that produced a minimum signal corresponding to maximum enzyme activity were created by using 5% DMSO instead of test compound.
  • Control wells that produced a maximum signal corresponding to fully inhibited enzyme were created by adding wortmannin (6 ⁇ M; Calbiochem / Merck Bioscience, Padge Road, Beeston, Nottingham, UK, Catalogue No. 681675) instead of test compound. These assay solutions were also agitated for 20 minutes at room temperature.
  • Biotinylated-DiC8-PI(3,4,5)P3 50 nM; Cell Signals Inc., Catalogue No. 107
  • recombinant purified GST-Grpl PH protein 2.5 nM
  • AlphaScreen Anti-GST donor and acceptor beads 100 ng; Packard Bioscience Limited, Station Road, Pangbourne, Berkshire, UK, Catalogue No. 6760603 M
  • the resultant signals arising from laser light excitation at 680 nm were read using a Packard AlphaQuest instrument.
  • PI(3,4,5)P3 is formed in situ as a result of PI3K mediated phosphorylation of PI(4,5)P2.
  • the GST-Grpl PH domain protein that is associated with AlphaScreen Anti-GST donor beads forms a complex with the biotinylated PI(3,4,5)P3 that is associated with Alphascreen Streptavidn acceptor beads.
  • the enymatically-produced PI(3,4,5)P3 competes with biotinylated PI(3,4,5)P3 for binding to the PH domain protein.
  • the donor bead : acceptor bead complex produces a signal that can be measured.
  • PI3K enzme activity to form PI(3,4,5)P3 and subsequent competition with biotinylated PI(3,4,5)P3 results in a reduced signal.
  • signal strength is recovered.
  • PI3K enzyme inhibition for a given test compound was expressed as an IC 50 value.
  • the assay used AlphaScreen technology (Gray et ah, Analytical Biochemistry. 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.
  • a C-terminal truncation of mTOR encompassing amino acid residues 1362 to 2549 of mTOR was stably expressed as a FLAG-tagged fusion in HEK293 cells as described by Vilella-Bach et ah, Journal of Biochemistry. 1999, 274, 4266- 4272.
  • the HEK293 FLAG-tagged mTOR (1362-2549) stable cell line was routinely maintained at 37°C with 5% CO 2 up to a confluency of 70-90% in Dulbecco's modified Eagle's growth medium (DMEM; Invitrogen Limited, Paisley, UK Catalogue No.
  • DMEM Dulbecco's modified Eagle's growth medium
  • Test compounds were prepared as 10 niM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ⁇ l) of each compound dilution were placed into a well of a Greiner 384- well low volume (LV) white polystyrene plate (Greiner Bio-one).
  • LV low volume
  • a 30 ⁇ l mixture of recombinant purified mTOR enzyme, 1 ⁇ M biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly- Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser- VaI-LyS-GIu-NH 2 ; Bachem UK Ltd), ATP (20 ⁇ M) and a buffer solution [comprising Tris-HCl ⁇ H7.4 buffer (50 niM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] was agitated at room temperature for 90 minutes.
  • biotinylated peptide substrate Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Le
  • Control wells that produced a maximum signal corresponding to maximum enzyme activity were created by using 5% DMSO instead of test compound.
  • Control wells that produced a minimum signal corresponding to fully inhibited enzyme were created by adding EDTA (83 mM) instead of test compound. These assay solutions were incubated for 2 hours at room temperature.
  • Phosphorylated biotinylated peptide is formed in situ as a result of mTOR mediated phosphorylation.
  • the phosphorylated biotinylated peptide that is associated with AlphaScreen Streptavidin donor beads forms a complex with the p70 S6 Kinase (T389) 1 A5 Monoclonal Antibody that is associated with Alphascreen Protein A acceptor beads.
  • the donor bead : acceptor bead complex produces a signal that can be measured. Accordingly, the presence of mTOR kinase activity results in an assay signal. In the presence of an mTOR kinase inhibitor, signal strength is reduced.
  • mTOR enzyme inhibition for a given test compound was expressed as an IC 50 value, (c) In Vitro phospho-Ser473 Akt assay
  • This assay determines the ability of test compounds to inhibit phosphorylation of Serine 473 in Akt as assessed using Acumen Explorer technology (TTP LabTech Limited, Royston, Herts, SG8 6EE, UK), a plate reader that can be used to rapidly quantitate features of images generated by laser-scanning.
  • a MDA-MB-468 human breast adenocarcinoma cell line (LGC Promochem, Teddington, Middlesex, UK, Catalogue No. HTB-132) was routinely maintained at 37°C with 5% CO 2 up to a confiuency of 70-90% in DMEM containing 10% FCS and 1% L-glutamine.
  • the cells were detached from the culture flask using 'Accutase' (Innovative Cell Technologies Inc., San Diego, CA, USA; Catalogue No. ATI 04) using standard tissue culture methods and resuspended in media to give 5.5x10 cells per ml. Aliquots (90 ⁇ l) were seeded into each of the inner 60 wells of a black 'Costar' 96-well plate (Corning Inc., NY, USA; Catalogue No. 3904) to give a density of -5000 cells per well. Aliquots (90 ⁇ l) of culture media were placed in the outer wells to prevent edge effects.
  • test compounds were prepared as 10 mM stock solutions in DMSO and serially diluted as required with DMSO and with growth media to give a range of concentrations that were 10-fold the required final test concentrations. Aliquots (10 ⁇ l) of each compound dilution were placed in duplicate wells to give the final required concentrations.
  • each plate contained wells having a final concentration of 30 ⁇ M LY294002 (Calbiochem, Beeston, UK 5 Catalogue No. 440202).
  • wells contained 0.5% DMSO instead of test compound.
  • Test compounds were prepared as 1OmM stock solutions in DMSO and aliquots (40 ⁇ l) of each compound were dispensed into one well of a quadrant of wells within a 384- well plate (Labcyte Inc., Catalogue No. P-05525-CV1).
  • concentrations of each compound were prepared in each quadrant of wells in the 384-well plate using a 'Hydra II' pipettor (Matrix Technologies Corporation, Handforth SK9 3LP, UK).
  • the permeabilsation/blocking buffer caused the cell wall to be partially degraded to allow immunostaining to proceed whilst blocking non-specific binding sites.
  • the buffer was removed and the cells were incubated for 16 hours at 4 0 C with rabbit anti-phospho-Akt (Ser473) antibody solution (50 ⁇ l per well; Cell Signaling Technology Inc., Hitchin, Herts, U.K., Catalogue No. 3787) that had been diluted 1:500 in 'blocking' buffer consisting of a mixture of PBS, 0.5% Tween-20 and 5% dried skimmed milk. Cells were washed three times in a mixture of PBS and 0.05% Tween- 20.
  • This assay determines the ability of test compounds to inhibit cell proliferation, as assessed by the extent of metabolism by living cells of a tetrazolium dye.
  • a MDA-MB-468 human breast carcinoma cell line (ATCC, Catalogue No. HTB-132) was routinely maintained as described in Biological Assay (c) hereinbefore except that the growth medium did not contain phenol red.
  • the cells were detached from the culture flask using 'Accutase' and, at a density of 4000 cells per well in 100 ⁇ l of complete growth medium, the cells were placed in wells in a 'Costar' 96-well tissue culture-treated plate (Corning Inc., Catalogue No. 3598). Aliquots (100 ⁇ l) per well of growth medium were added to some wells to provide blank values for the colorometric measurement. The cells were incubated overnight at 37 0 C with 5% CO 2 to allow them to adhere.
  • Test compounds were prepared as 10 mM stock solutions in DMSO and serially diluted with growth medium to give a range of test concentrations. An aliquot (50 ⁇ l) of each compound dilution was placed in a well in the 96-well plates. Each plate contained control wells without test compound. With the exception of wells containing the plate blanks, the outer wells on each 96-well plate were not used. The cells were incubated for 72 hours at 37°C with 5% CO 2 . An aliquot (30 ⁇ l) of the MTS/PES solution was added to each well and the cells were incubated for 2 hours at 37°C with 5% CO 2 . The optical density was measured on a plate reader using a wavelength of 492nm.
  • This test measures the ability of compounds to inhibit the growth of MDA-MB-468 human breast adenocarcinoma cells grown as a tumour in athymic nude mice (Alderley Park nu/nu strain).
  • a total of about 5 x 10 6 MDA-MB-468 cells in matrigel (Beckton Dickinson Catalogue No. 40234) are injected subcutaneously into the left flank of each test mouse and the resultant tumours are allowed to grow for about 14 days. Tumour size is measured twice weekly using callipers and a theoretical volume is calculated. Animals are selected to provide control and treatment groups of approximately equal average tumour volume.
  • Test compounds are prepared as a ball-milled suspension in 1% polysorbate vehicle and dosed orally once daily for a period of about 28 days. The effect on tumour growth is assessed.
  • the indole compound disclosed within Example 1 possesses activity in Test (a) with an IC 50 versus pi 10a Type Ia human PI3K of approximately 0.5 ⁇ M, in Test (b) with an IC 50 versus mTOR PI kinase-related kinase of approximately 1 ⁇ M, and in Test (c) with an IC 50 of approximately 13 ⁇ M.
  • the indole compound disclosed as Compound No. 1 within Example 2 possesses activity in Test (a) with an IC 5 O versus pi 10a Type Ia human PI3K of approximately 0.5 ⁇ M, and in Test (c) with an IC 5O of approximately 17 ⁇ M.
  • the indole compound disclosed within Example 3 possesses activity in Test (a) with an IC 50 versus pi 10a Type Ia human PI3K of approximately 0.2 ⁇ M, and in Test (c) with an IC 50 of approximately 5 ⁇ M.
  • the indole compound disclosed as Compound No. 1 within Example 4 possesses activity in Test (a) with an IC 50 versus pi 10a Type Ia human PDK of approximately 0.1 ⁇ M, and in Test (c) with an ICs 0 of approximately 2 ⁇ M.
  • the indole compound disclosed within Example 7 possesses activity in Test (a) with an IC 50 versus pi 10a Type Ia human PI3K of approximately 0.5 ⁇ M, and in Test (c) with an IC 50 of approximately 2 ⁇ M.
  • the indole compound disclosed within Example 8 possesses activity in Test (a) with an IC 50 versus pi 10a Type Ia human PI3K of approximately 0.1 ⁇ M, and in Test (c) with an IC 50 of approximately 3 ⁇ M.
  • a pharmaceutical composition which comprises an indole derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
  • compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intraperitoneal or intramuscular dosing) or for rectal administration (for example as a suppository).
  • oral use for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or e
  • compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
  • compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
  • a formulation intended for oral administration to humans will generally contain, for example, from 1 mg to 1 g of active agent (more suitably from 1 to 250 mg, for example from 1 to 100 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
  • the size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the disease state, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.
  • a daily dose in the range for example, 1 mg/kg to 100 mg/kg body weight is received, given if required in divided doses.
  • lower doses will be administered when a parenteral route is employed.
  • a dose in the range for example, 1 mg/kg to 25 mg/kg body weight will generally be used.
  • a dose in the range for example, 1 mg/kg to 25 mg/kg body weight will be used.
  • Oral administration is however preferred, particularly in tablet form.
  • unit dosage forms will contain about 10 mg to 0.5 g of a compound of this invention.
  • PI3K enzymes contribute to tumourigenesis by one or more of the effects of mediating proliferation of cancer and other cells, mediating angiogenic events and mediating the motility, migration and invasiveness of cancer cells.
  • the indole derivatives of the present invention possess potent anti-tumour activity which it is believed is obtained by way of inhibition of one or more of the Class I PBK enzymes (such as the Class Ia PBK enzymes and/or the Class Ib PBK enzyme) and/or a mTOR kinase (such as a mTOR PI kinase-related kinase) that are involved in the signal transduction steps which lead to the proliferation and survival of tumour cells and the invasiveness and migratory ability of metastasising tumour cells.
  • the Class I PBK enzymes such as the Class Ia PBK enzymes and/or the Class Ib PBK enzyme
  • a mTOR kinase such as a mTOR PI kinase-related
  • the derivatives of the present invention are of value as anti-tumour agents, in particular as selective inhibitors of the proliferation, survival, motility, dissemination and invasiveness of mammalian cancer cells leading to inhibition of tumour growth and survival and to inhibition of metastatic tumour growth.
  • the indole derivatives of the present invention are of value as anti-proliferative and anti-invasive agents in the containment and/or treatment of solid tumour disease.
  • the compounds of the present invention are expected to be useful in the prevention or treatment of those tumours which are sensitive to inhibition of one or more of the multiple PI3K enzymes such as the Class Ia PBK enzymes and the Class Ib PBK enzyme that are involved in the signal transduction steps which lead to the proliferation and survival of tumour cells and the migratory ability and invasiveness of metastasising tumour cells.
  • the compounds of the present invention are expected to be useful in the prevention or treatment of those tumours which are mediated alone or in part by inhibition of PBK enzymes such as the Class Ia PBK enzymes and the Class Ib PBK enzyme, i.e. the compounds may be used to produce a PBK enzyme inhibitory effect in a warm-blooded animal in need of such treatment.
  • inhibitors of PBK enzymes should be of therapeutic value for treatment of, for example, cancer of the breast, colorectum, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer) and prostate, and of cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix and vulva, and of leukaemias [including acute lymphoctic leukaemia (ALL) and chronic myelogenous leukaemia (CML)], multiple myeloma and lymphomas.
  • ALL acute lymphoctic leukaemia
  • CML chronic myelogenous leukaemia
  • an indole derivative of the Formula I or a pharmaceutically-acceptable salt thereof, as defined hereinbefore for the production of an anti-proliferative effect in a warm-blooded animal such as man.
  • an indole derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in a warm-blooded animal such as man as an anti-invasive agent in the containment and/or treatment of solid tumour disease.
  • a method for producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of an indole derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.
  • a method for producing an anti-invasive effect by the containment and/or treatment- of solid tumour disease in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of an indole derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.
  • an indole derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the prevention or treatment of solid tumour disease in a warm-blooded animal such as man.
  • a method for the prevention or treatment of solid tumour disease in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of an indole derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.
  • PI3K enzymes such as the Class Ia enzymes and/or the Class Ib PI3K enzyme
  • a mTOR kinase such as a mTOR PI kinase-related kinase
  • PDK enzymes such as the Class Ia enzymes and/or the Class Ib PDK enzyme
  • a mTOR kinase such as a mTOR PI kinase-related kinase
  • tumours which are sensitive to inhibition of PDK enzymes (such as the Class Ia enzymes and/or the Class Ib PDK enzyme) and/or a mTOR kinase (such as a mTOR PI kinase-related kinase) that are involved in the signal transduction steps which lead to the proliferation, survival, invasiveness and migratory ability of tumour cells
  • PDK enzymes such as the Class Ia enzymes and/or the Class Ib PDK enzyme
  • a mTOR kinase such as a mTOR PI kinase-related kinase
  • a PDK enzyme inhibitory effect such as a Class Ia PDK enzyme or Class Ib PDK enzyme inhibitory effect
  • a mTOR kinase inhibitory effect such as a mTOR PI kinase- related kinase inhibitory effect
  • a PDK enzyme inhibitory effect such as a Class Ia PDK enzyme or Class Ib PDK enzyme inhibitory effect
  • a mTOR kinase inhibitory effect such as a mTOR PI kinase-related kinase inhibitory effect
  • a method for providing a PDK enzyme inhibitory effect such as a Class Ia PDK enzyme or Class Ib PDK enzyme inhibitory effect
  • a mTOR kinase inhibitory effect such as a mTOR PI kinase- related kinase inhibitory effect
  • certain compounds of the present invention possess better potency against Class Ia PI3K enzymes and against a mTOR kinase (such as a mTOR PI kinase-related kinase) than against EGF receptor tyrosine kinase, VEGF receptor tyrosine kinase or Src non-receptor tyrosine kinase enzymes.
  • a mTOR kinase such as a mTOR PI kinase-related kinase
  • Such compounds may possess sufficient potency against Class Ia PI3K enzymes and mTOR kinases that they may be used in an amount sufficient to inhibit Class Ia PI3K enzymes and nTOR kinases whilst demonstrating little activity against EGF receptor tyrosine kinase, VEGF receptor tyrosine kinase or Src non-receptor tyrosine kinase enzymes.
  • Such compounds are likely to be useful for the selective inhibition of Class Ia PI3K enzymes and mTOR kinases and are likely to be useful for the effective treatment of, for example, Class Ia PI3K enzyme driven tumours.
  • an indole derivative of the Formula I or a pharmaceutically-acceptable salt thereof, as defined hereinbefore for use in providing a selective Class Ia PI3K enzyme and/or mTOR kinase inhibitory effect.
  • a method for providing a selective Class Ia PI3 K enzyme and/or mTOR kinase inhibitory effect which comprises administering an effective amount of an indole derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.
  • a selective Class Ia PI3K enzyme inhibitory effect is meant that the indole derivatives of the Formula I are more potent against Class Ia PI3K enzymes and/or mTOR kinases than against many other kinase enzymes.
  • some of the compounds according to the invention are more potent against Class Ia PI3K enzymes and/or mTOR kinases than against other kinases such as other receptor or non-receptor tyrosine kinases or serine/threonine kinases.
  • a selective Class Ia PI3K enzyme inhibitor according to the invention would be at least 5 times more potent, preferably at least 10 times more potent, more preferably at least 100 times more potent, against Class Ia PI3K enzymes than against other kinases such as EGF receptor tyrosine kinase, VEGF receptor tyrosine kinases or Src non-receptor tyrosine kinases.
  • leukaemias including ALL and CML
  • leukaemias including ALL and CML
  • a method for treating cancer of the breast, colorectum, lung (including small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer) and prostate in a warm blooded animal such as man that is in need of such treatment which comprises administering an effective amount of an indole derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.
  • a method for treating cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix and vulva, and of leukaemias (including ALL and CML), multiple myeloma and lymphomas in a warm blooded animal such as man that is in need of such treatment which comprises administering an effective amount of an indole derivative of the Formula I 5 or a pharmaceutically-acceptable salt thereof, as defined hereinbefore.
  • the in vivo effects of a compound of the Formula I may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of the Formula I.
  • anti-cancer treatment may be applied as a sole therapy or may involve, in addition to the indole derivative of the invention, conventional surgery or radiotherapy or chemotherapy.
  • chemotherapy may include one or more of the following categories of anti-tumour agents :-
  • antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology such as alkylating agents (for example cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and gemcitabine); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine
  • cytostatic agents such as antioestrogens (for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 ⁇ -reductase such as finasteride;
  • antioestrogens for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene
  • antiandrogens for example
  • anti-invasion agents for example c-Src kinase family inhibitors like 4-(6-chloro- 2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-l-yl)ethoxy]-5-tetrahydropyran- 4-yloxyquinazoline (AZD0530; International Patent Application WO 01/94341) and bosutinib (SKI-606), and metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function];
  • inhibitors of growth factor function for example such inhibitors include growth factor antibodies and growth factor receptor antibodies [for example the anti-erbB2 antibody trastuzumab and the anti-erbBl antibodies cetuximab (C225) and panitumumab]; such inhibitors also include, for example, tyrosine kinase inhibitors [for example inhibitors of the epidermal growth
  • vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213;
  • antisense therapies for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;
  • gene therapy approaches including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and
  • immunotherapy approaches including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.
  • cytokines such as interleukin 2, interleukin 4 or granulocyte-ma
  • Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
  • Such combination products employ the compounds of this invention within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.
  • a pharmaceutical product comprising an indole derivative of the Formula I as defined hereinbefore and an additional anti-tumour agent as defined hereinbefore for the conjoint treatment of cancer.
  • the compounds of the Formula I are primarily of value as therapeutic agents for use in warm-blooded animals (including man), they are also useful whenever it is required to inhibit the effects of PI3K enzymes and/or mTOR kinases. Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.
  • reactions may be conducted under microwave radiation using an instrument such as a 'Smith Synthesiser' (300 KWatts) on either the normal or high setting, which instrument makes use of a temperature probe to adjust the microwave power ouput automatically in order to maintain the required temperature; alternatively an 'Emrys Optimizer' microwave instrument may be used;
  • Method Bl Phenomenex 'Gemini' Cl 8 column (5 microns silica, 2 mm diameter, 50 mm length) using a Solvent A comprising 0.1% aqueous ammonium hydroxide and a Solvent B of acetonitrile, a solvent gradient over 4 minutes from a 19: 1 mixture of Solvents A and B to a 1 : 19 mixture of Solvents A and B and a flow rate of 1.2 ml per minute;
  • Methanesulphonyl chloride (0.053 ml) was added dropwise to a stirred mixture of 5-(5-amino-6-chloropyridin-3-yl)-lH " -pyrrolo[2,3-b]pyridine (0.15 g), triethylamine (0.5 ml) and T ⁇ F (8 ml) that had been cooled to 0°C in an ice bath and the resultant mixture was stirred at O 0 C for 15 minutes. The mixture was allowed to warm to ambient temperature and was stirred for 16 hours. Water (1 ml) and 7M ammonia in methanol (4 ml) were added in turn and the resultant mixture was stirred 2 hours.
  • the mixture was concentrated by evaporation and the residue was purified by preparative reversed-phase chromatography using a Gilson ⁇ PLC instrument with a Waters 'Xterra' Cl 8 column (5 microns silica, 19 mm diameter, 100 mm length) and decreasingly polar mixtures of 0.1% aqueous ammonium hydroxide and acetonitrile as eluent.
  • the organic solution was dried over magnesium sulphate and evaporated.
  • the material so obtained was purified by column chromatography on silica using a 40: 1 mixture of methylene chloride and a 7M methanolic ammonia solution as eluent.
  • each reaction product was purified by preparative reversed- phase chromatography using a Waters 'Xterra' Cl 8 column (5 microns silica, 19 mm diameter, 100 mm length) and decreasingly polar mixtures of 0.1% aqueous ammonium hydroxide and acetonitrile as eluent.
  • Benzenesulphonyl chloride (0.312 ml) was added to a mixture of 5-(5-amino- 6-chloropyridin-3-yl)-l//-pyrrolo[2,3-b]pyridine (0.2 g) and pyridine (6 ml) and the resultant mixture was stirred and heated to 55°C for 3 hours. The mixture was evaporated. Pyrrolidine (4 ml) was added and the mixture was stirred at ambient temperature for 30 minutes.
  • each reaction product was purified by preparative reversed- phase chromatography using a Waters 'Xterra' Cl 8 column (5 microns silica, 19 mm diameter, 100 mm length) and decreasingly polar mixtures of 0.1% aqueous ammonium hydroxide and acetonitrile as eluent.
  • the 2,4-dimethylthiazol-5-ylsulphonyl chloride starting material is commercially available and is also described in J. Het. Chem., 1981, 18, 997.
  • the material may also be prepared as follows :-
  • Chlorosulphonic acid (20 ml) was cooled to 15 0 C in an ice/methanol bath. 2,4-Dimethylthiazole (11.32 g) was added dropwise over 45 minutes, with the evolution of hydrogen chloride gas during the addition. The mixture so obtained was heated to 140-150 0 C for 16 hours. The resultant mixture was cooled to 110-120 0 C and finely powdered phosphorus pentachloride (41.6 g) was added in small portions, with the evolution of further hydrogen chloride gas during the addition. The mixture so obtained was heated to 12O 0 C for 1 hour. The mixture was cooled to ambient temperature and poured slowly into a vigorously stirred mixture of ice (200 g) and water (200 ml).
  • each reaction product was purified by preparative reversed- phase chromatography using a Waters 'Xterra' Cl 8 column (5 microns silica, 19 mm diameter, 100 mm length) and decreasingly polar mixtures of 0.1% aqueous ammonium hydroxide and acetonitrile as eluent.
  • Benzenesulphonyl chloride (0.132 ml) was added to a mixture of 6-(5-amino- 6-chloropyridin-3-yl)-5-methyl-3-(2-trimethylsilylethoxymethyl)-3H-imidazo[4,5-Z']pyridine (0.135 g) and pyridine (4 ml) that had been cooled to 0 0 C. The resultant mixture was stirred at 0 0 C for 2 hours and at ambient temperature for 4 hours. A second portion of benzenesulphonyl chloride (0.044 ml) was added and the mixture was stirred at ambient temperature for 18 hours. Water was added and the mixture was evaporated. The residue was partitioned between ethyl acetate and water.
  • the organic extract was washed with water and with brine, dried over anhydrous sodium sulphate and evaporated.
  • the material so obtained was dissolved in a mixture of methanol (4 ml) and water (0.5 ml) and macroporous polystyrene carbonate resin (MP carbonate resin, 2.91 mM/g, 0.59 g; Argonaut Technologies , New Road, Hengoed, Mid Glamorgan United Kingdom, CF82 8AU) was added and the mixture was stirred for 3 hours. A second portion of the resin (0.5 g) was added and the mixture was stirred for 20 hours. The resin was isolated on a filter and washed with methanol.
  • the material so obtained was cooled in ice and water (0.6 ml) and trifluoroacetic acid (2.4 ml) were added. The resultant mixture was stirred at O 0 C for 10 minutes and at ambient temperature for 3 hours. The mixture was evaporated and the residue was dissolved in methanol and the solution was passed down an 'Isolute SCX-2' column (10 g) by initially washing the column with methanol, followed by elution with a 2M methanolic ammonia solution. The material so obtained was purified by column chromatography on silica using a stepwise gradient (97:3 to 94:6) of methylene chloride and methanol as eluent.
  • the organic extract was washed with water and with brine, dried over anhydrous sodium sulphate and evaporated.
  • the material so obtained was purified by column chromatography on silica using a 4: 1 mixture of isohexane and ethyl acetate as eluent.
  • the organic solution was washed with water and with brine, dried over anhydrous sodium sulphate and evaporated.
  • the material so obtained was purified by column chromatography on silica using a gradient from 99:1 to 9:1 of methylene chloride and methanol as eluent.
  • Trifluoroacetic acid (0.75 ml) and iV-iodosuccinimide (18.05 g) were added in turn to a mixture of 6-ammo-3-bromo-2-methylpyridine (15 g) and acetic acid (150 ml) and the resultant mixture was stirred at ambient temperature for 3 hours.
  • the reaction mixture was poured onto a mixture of ice and water and neutralised by the addition of a 28% aqueous ammonia hydroxide solution. The precipitate was isolated and dried under vacuum at 45°C for 72 hours.
  • Cuprous iodide (0.122 g) was added to a mixture of 2-amino-5-bromo-3-iodo- 6-methylpyridine (10 g), triethylamine (200 ml) and THF (40 ml) and the resultant mixture was purged with nitrogen gas.
  • Trimethylsilylacetylene (5.42 ml) and bis(triphenylphosphino)palladium( ⁇ ) chloride (0.449 g) were added in turn and the reaction mixture was purged with nitrogen gas after each addition. Under an atmosphere of nitrogen, the resultant reaction mixture was stirred at ambient temperature for 4 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and water.
  • the material so obtained was further purified by preparative reversed-phase chromatography using a Waters 'Xterra' Cl 8 column (5 microns silica, 19 mm diameter, 100 mm length) and decreasingly polar mixtures of 0.1% aqueous ammonium hydroxide and acetonitrile as eluent.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention se rapporte à des dérivés de l'indole de Formule (I) ou à des sels pharmaceutiquement acceptables de ceux-ci, dans lesquels chacun parmi le Cycle A, m, R1, R2, n, R3 et G1 représente l'une quelconque des significations définies dans la description. L'invention décrit des procédés de préparation, des compositions pharmaceutiques les contenant et leur utilisation en thérapie, par exemple dans le traitement de maladie à médiation par une enzyme PI3K et/ou une kinase mTOR.
PCT/GB2007/001858 2006-05-22 2007-05-18 Dérivés de l'indole WO2007135398A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/301,722 US20090306126A1 (en) 2006-05-22 2007-05-18 Indole Derivatives
JP2009511568A JP2009537621A (ja) 2006-05-22 2007-05-18 インドール誘導体
EP07732879A EP2029593A1 (fr) 2006-05-22 2007-05-18 Dérivés de l'indole

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06300505 2006-05-22
EP06300505.2 2006-05-22

Publications (1)

Publication Number Publication Date
WO2007135398A1 true WO2007135398A1 (fr) 2007-11-29

Family

ID=38420695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/001858 WO2007135398A1 (fr) 2006-05-22 2007-05-18 Dérivés de l'indole

Country Status (5)

Country Link
US (1) US20090306126A1 (fr)
EP (1) EP2029593A1 (fr)
JP (1) JP2009537621A (fr)
CN (1) CN101448827A (fr)
WO (1) WO2007135398A1 (fr)

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110508A1 (fr) * 2007-03-09 2008-09-18 Glaxo Group Limited Composés
WO2009155052A1 (fr) * 2008-05-28 2009-12-23 Wyeth Composés de 1h-pyrrolo[2,3-b]pyridine substituée en position 3 et composés de 1h-pyrrolo[3,2-b]pyridine substituée en position 3, leur utilisation en tant qu’inhibiteurs de kinase mtor et pi3 kinase, et leur synthèses
WO2010016490A1 (fr) 2008-08-05 2010-02-11 第一三共株式会社 Dérivé d'imidazopyridin-2-one
WO2010030727A1 (fr) * 2008-09-10 2010-03-18 Wyeth Llc Composés 1h—indole substitué en position 3, 1h-pyrrolo[2,3-b]pyridine substituée en position 3 et 1h-pyrrolo[3,2-b]pyridine substituée en position 3, leur utilisation comme mtor kinase et inhibiteurs de la pi3 kinase, et leurs synthèses
DE102008052943A1 (de) 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
WO2010059788A1 (fr) * 2008-11-20 2010-05-27 Genentech, Inc. Composés inhibiteurs de pi3k de type pyrazolopyridine et leurs procédés d'utilisation
EP2211615A1 (fr) * 2007-10-22 2010-08-04 GlaxoSmithKline LLC Dérivés de pyridosulfonamide en tant qu'inhibiteurs de pi3 kinase
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
WO2010125799A1 (fr) 2009-04-27 2010-11-04 塩野義製薬株式会社 Dérivé d'urée présentant une activité inhibitrice de la pi3k
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
WO2013019927A1 (fr) 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification d'un profil d'expression génique à titre de biomarqueur prédictif de l'état lkb1
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8569323B2 (en) 2009-07-15 2013-10-29 Intellikine, Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8729074B2 (en) 2009-03-20 2014-05-20 Amgen Inc. Inhibitors of PI3 kinase
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
EP2762142A1 (fr) 2009-10-30 2014-08-06 ARIAD Pharmaceuticals, Inc. Compositions pour le traitement du cancer
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8815918B2 (en) 2009-04-02 2014-08-26 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9155736B2 (en) 2012-10-18 2015-10-13 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2992878A1 (fr) 2010-02-03 2016-03-09 Signal Pharmaceuticals, LLC Identification d'une mutation lkb1 comme biomarqueur prédictif de la sensibilité aux inhibiteurs de la kinase tor
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359364B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one
US9358232B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US9416134B2 (en) 2014-04-16 2016-08-16 Signal Pharmaceuticals, Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, as TOR kinase inhibitors
US9474757B2 (en) 2013-04-17 2016-10-25 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
US9604939B2 (en) 2013-05-29 2017-03-28 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
US9630966B2 (en) 2013-04-17 2017-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US9629843B2 (en) 2008-07-08 2017-04-25 The Regents Of The University Of California MTOR modulators and uses thereof
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US9751854B2 (en) 2014-01-14 2017-09-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
US9937169B2 (en) 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
WO2018154133A1 (fr) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US10336775B2 (en) 2014-08-28 2019-07-02 Asceneuron Sa Glycosidase inhibitors
US10556902B2 (en) 2016-02-25 2020-02-11 Asceneuron Sa Glycosidase inhibitors
US10696668B2 (en) 2016-02-25 2020-06-30 Asceneuron Sa Acid addition salts of piperazine derivatives
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11096940B2 (en) 2017-06-22 2021-08-24 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
US11612599B2 (en) 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
US11944606B2 (en) 2017-03-15 2024-04-02 Genentech, Inc. Azaindoles as inhibitors of HPK1
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009324894B2 (en) * 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
KR101236731B1 (ko) * 2010-11-02 2013-02-25 한국과학기술원 아자인돌 화합물, 이를 포함하는 ｐｉ３ｋ 저해제용 약학 조성물 및 ｐｉ３ｋ와 연관된 질환 치료용 약학 조성물
CN104761491B (zh) * 2015-03-31 2018-08-21 山东友帮生化科技有限公司 2-氨基-3-碘-5-溴吡啶的合成方法
CN108368111B (zh) * 2015-12-16 2020-07-31 上海嘉坦医药科技有限公司 吡啶并[1,2-a]嘧啶酮类似物的晶型及其制备方法和中间体
CN106117181A (zh) * 2016-06-28 2016-11-16 复旦大学 Pi3k抑制剂及其制备方法与在制药中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003082869A1 (fr) * 2002-03-28 2003-10-09 Eisai Co., Ltd. Azaindoles en tant qu'inhibiteurs de kinases a terminaison c-jun n
WO2004058176A2 (fr) * 2002-12-20 2004-07-15 Pharmacia Corporation Composes de pyrazole acyclique pour l'inhibition d'une proteine kinase activee par mitogene / d'une proteine kinase 2 activee
WO2004078757A2 (fr) * 2003-03-06 2004-09-16 Eisai Co., Ltd. Synthese
WO2005062795A2 (fr) * 2003-12-19 2005-07-14 Plexxikon, Inc. Composes et methodes de developpement de modulateurs de ret
WO2005100353A1 (fr) * 2004-04-15 2005-10-27 Almirall Prodesfarma, Sa Derives de pyridine condenses utiles comme antagonistes du recepteur de l'adenosine a28
WO2006124863A2 (fr) * 2005-05-16 2006-11-23 Irm Llc Composes et compositions en tant qu'inhibiteurs de proteine kinase
WO2007002325A1 (fr) * 2005-06-22 2007-01-04 Plexxikon, Inc. Composes et methodes de modulation de la kinase et instructions afferentes

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003082869A1 (fr) * 2002-03-28 2003-10-09 Eisai Co., Ltd. Azaindoles en tant qu'inhibiteurs de kinases a terminaison c-jun n
WO2004058176A2 (fr) * 2002-12-20 2004-07-15 Pharmacia Corporation Composes de pyrazole acyclique pour l'inhibition d'une proteine kinase activee par mitogene / d'une proteine kinase 2 activee
WO2004078757A2 (fr) * 2003-03-06 2004-09-16 Eisai Co., Ltd. Synthese
WO2005062795A2 (fr) * 2003-12-19 2005-07-14 Plexxikon, Inc. Composes et methodes de developpement de modulateurs de ret
WO2005100353A1 (fr) * 2004-04-15 2005-10-27 Almirall Prodesfarma, Sa Derives de pyridine condenses utiles comme antagonistes du recepteur de l'adenosine a28
WO2006124863A2 (fr) * 2005-05-16 2006-11-23 Irm Llc Composes et compositions en tant qu'inhibiteurs de proteine kinase
WO2007002325A1 (fr) * 2005-06-22 2007-01-04 Plexxikon, Inc. Composes et methodes de modulation de la kinase et instructions afferentes

Cited By (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US9493467B2 (en) 2006-04-04 2016-11-15 The Regents Of The University Of California PI3 kinase antagonists
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
WO2008110508A1 (fr) * 2007-03-09 2008-09-18 Glaxo Group Limited Composés
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
JP2011500823A (ja) * 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
EP2211615A4 (fr) * 2007-10-22 2010-10-13 Glaxosmithkline Llc Dérivés de pyridosulfonamide en tant qu'inhibiteurs de pi3 kinase
EP2211615A1 (fr) * 2007-10-22 2010-08-04 GlaxoSmithKline LLC Dérivés de pyridosulfonamide en tant qu'inhibiteurs de pi3 kinase
JP2011507854A (ja) * 2007-12-19 2011-03-10 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
US9822131B2 (en) 2008-01-04 2017-11-21 Intellikine Llc Certain chemical entities, compositions and methods
US9216982B2 (en) 2008-01-04 2015-12-22 Intellikine Llc Certain chemical entities, compositions and methods
US9655892B2 (en) 2008-01-04 2017-05-23 Intellikine Llc Certain chemical entities, compositions and methods
US11433065B2 (en) 2008-01-04 2022-09-06 Intellikine Llc Certain chemical entities, compositions and methods
US8785456B2 (en) 2008-01-04 2014-07-22 Intellikine Llc Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9637492B2 (en) 2008-03-14 2017-05-02 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009155052A1 (fr) * 2008-05-28 2009-12-23 Wyeth Composés de 1h-pyrrolo[2,3-b]pyridine substituée en position 3 et composés de 1h-pyrrolo[3,2-b]pyridine substituée en position 3, leur utilisation en tant qu’inhibiteurs de kinase mtor et pi3 kinase, et leur synthèses
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
US9629843B2 (en) 2008-07-08 2017-04-25 The Regents Of The University Of California MTOR modulators and uses thereof
US9828378B2 (en) 2008-07-08 2017-11-28 Intellikine Llc Kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US8436012B2 (en) 2008-08-05 2013-05-07 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
WO2010016490A1 (fr) 2008-08-05 2010-02-11 第一三共株式会社 Dérivé d'imidazopyridin-2-one
US8785438B2 (en) 2008-08-05 2014-07-22 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
WO2010030727A1 (fr) * 2008-09-10 2010-03-18 Wyeth Llc Composés 1h—indole substitué en position 3, 1h-pyrrolo[2,3-b]pyridine substituée en position 3 et 1h-pyrrolo[3,2-b]pyridine substituée en position 3, leur utilisation comme mtor kinase et inhibiteurs de la pi3 kinase, et leurs synthèses
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US9790228B2 (en) 2008-09-26 2017-10-17 Intellikine Llc Heterocyclic kinase inhibitors
US9296742B2 (en) 2008-09-26 2016-03-29 Intellikine Llc Heterocyclic kinase inhibitors
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
DE102008052943A1 (de) 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CN102224152B (zh) * 2008-11-20 2014-05-21 健泰科生物技术公司 吡唑并吡啶pi3k抑制剂化合物及使用方法
CN102224152A (zh) * 2008-11-20 2011-10-19 健泰科生物技术公司 吡唑并吡啶pi3k抑制剂化合物及使用方法
WO2010059788A1 (fr) * 2008-11-20 2010-05-27 Genentech, Inc. Composés inhibiteurs de pi3k de type pyrazolopyridine et leurs procédés d'utilisation
US8729074B2 (en) 2009-03-20 2014-05-20 Amgen Inc. Inhibitors of PI3 kinase
US8815918B2 (en) 2009-04-02 2014-08-26 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives
WO2010125799A1 (fr) 2009-04-27 2010-11-04 塩野義製薬株式会社 Dérivé d'urée présentant une activité inhibitrice de la pi3k
US9315505B2 (en) 2009-05-07 2016-04-19 Intellikine Llc Heterocyclic compounds and uses thereof
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US9522146B2 (en) 2009-07-15 2016-12-20 Intellikine Llc Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8569323B2 (en) 2009-07-15 2013-10-29 Intellikine, Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
EP2762142A1 (fr) 2009-10-30 2014-08-06 ARIAD Pharmaceuticals, Inc. Compositions pour le traitement du cancer
US9555033B2 (en) 2010-02-03 2017-01-31 Signal Pharmaceuticals, Llc Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors
EP2992878A1 (fr) 2010-02-03 2016-03-09 Signal Pharmaceuticals, LLC Identification d'une mutation lkb1 comme biomarqueur prédictif de la sensibilité aux inhibiteurs de la kinase tor
US9181221B2 (en) 2010-05-21 2015-11-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9738644B2 (en) 2010-05-21 2017-08-22 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9388183B2 (en) 2010-11-10 2016-07-12 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US10550122B2 (en) 2011-01-10 2020-02-04 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof
US9840505B2 (en) 2011-01-10 2017-12-12 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
US11312718B2 (en) 2011-01-10 2022-04-26 Infinity Pharmaceuticals, Inc. Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
USRE46621E1 (en) 2011-01-10 2017-12-05 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9669028B2 (en) 2011-03-30 2017-06-06 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
US9187473B2 (en) 2011-03-30 2015-11-17 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
US9962382B2 (en) 2011-03-30 2018-05-08 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9718815B2 (en) 2011-07-19 2017-08-01 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9605003B2 (en) 2011-07-19 2017-03-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013019927A1 (fr) 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification d'un profil d'expression génique à titre de biomarqueur prédictif de l'état lkb1
US9546180B2 (en) 2011-08-29 2017-01-17 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9115141B2 (en) 2011-08-29 2015-08-25 Infinity Pharmaceuticals, Inc. Substituted isoquinolinones and methods of treatment thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9895373B2 (en) 2011-09-02 2018-02-20 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US11613544B2 (en) 2012-09-26 2023-03-28 The Regents Of The University Of California Substituted imidazo[1,5-a]pyrazines for modulation of IRE1
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US10822340B2 (en) 2012-09-26 2020-11-03 The Regents Of The University Of California Substituted imidazolopyrazine compounds and methods of using same
US9557338B2 (en) 2012-10-18 2017-01-31 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activity
US9155736B2 (en) 2012-10-18 2015-10-13 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US10183019B2 (en) 2013-04-17 2019-01-22 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
US9980963B2 (en) 2013-04-17 2018-05-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US10052322B2 (en) 2013-04-17 2018-08-21 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one
US9630966B2 (en) 2013-04-17 2017-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US9827243B2 (en) 2013-04-17 2017-11-28 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one
US10391092B2 (en) 2013-04-17 2019-08-27 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
US9358232B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US9359364B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one
US9474757B2 (en) 2013-04-17 2016-10-25 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
US9937169B2 (en) 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
US10052323B2 (en) 2013-05-29 2018-08-21 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use
US9604939B2 (en) 2013-05-29 2017-03-28 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
US9974786B2 (en) 2013-05-29 2018-05-22 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3- B]pyrazin-2(1H)-one, a solid form there of and methods of their use
US9795603B2 (en) 2013-05-29 2017-10-24 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10329299B2 (en) 2013-10-04 2019-06-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9828377B2 (en) 2013-10-04 2017-11-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9802960B2 (en) 2014-01-14 2017-10-31 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US10538533B2 (en) 2014-01-14 2020-01-21 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9751854B2 (en) 2014-01-14 2017-09-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US11541059B2 (en) 2014-03-19 2023-01-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10675286B2 (en) 2014-03-19 2020-06-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9981971B2 (en) 2014-04-16 2018-05-29 Signal Pharmaceuticals, Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one as TOR kinase inhibitors
US11944631B2 (en) 2014-04-16 2024-04-02 Infinity Pharmaceuticals, Inc. Combination therapies
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
US9416134B2 (en) 2014-04-16 2016-08-16 Signal Pharmaceuticals, Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, as TOR kinase inhibitors
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US9975898B2 (en) 2014-04-16 2018-05-22 Signal Pharmaceuticals, Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-YL)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one as tor kinase inhibitors
US10336775B2 (en) 2014-08-28 2019-07-02 Asceneuron Sa Glycosidase inhibitors
US11046712B2 (en) 2014-08-28 2021-06-29 Asceneuron Sa Glycosidase inhibitors
US10941162B2 (en) 2014-10-03 2021-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10253047B2 (en) 2014-10-03 2019-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11939333B2 (en) 2015-09-14 2024-03-26 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US11247995B2 (en) 2015-09-14 2022-02-15 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10696668B2 (en) 2016-02-25 2020-06-30 Asceneuron Sa Acid addition salts of piperazine derivatives
US11612599B2 (en) 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
US10556902B2 (en) 2016-02-25 2020-02-11 Asceneuron Sa Glycosidase inhibitors
US10995090B2 (en) 2016-02-25 2021-05-04 Asceneuron Sa Substituted dihydrobenzofuran glycosidase inhibitors
US11591327B2 (en) 2016-02-25 2023-02-28 Asceneuron Sa Acid addition salts of piperazine derivatives
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
WO2018154133A1 (fr) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga
US11944606B2 (en) 2017-03-15 2024-04-02 Genentech, Inc. Azaindoles as inhibitors of HPK1
US11096940B2 (en) 2017-06-22 2021-08-24 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors

Also Published As

Publication number Publication date
JP2009537621A (ja) 2009-10-29
US20090306126A1 (en) 2009-12-10
CN101448827A (zh) 2009-06-03
EP2029593A1 (fr) 2009-03-04

Similar Documents

Publication Publication Date Title
US20090306126A1 (en) Indole Derivatives
US20090118336A1 (en) Pyrazole derivatives and their use as pi3k inhibitors
US20090076009A1 (en) Thiazole derivatives and their use as anti-tumour agents
EP1768978B1 (fr) Pyrimidines a substitution triple aux positions 2, 4, 6 utilises en tant qu'inhibiteurs de phosphotidylinositol (pi) 3-kinase et utilisations de celles-ci pour traiter un cancer
US7893063B2 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
US20090233926A1 (en) 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20090325954A1 (en) 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2007066099A1 (fr) Derives de pyrimidine
WO2007066102A1 (fr) Derives de pyrimidine
WO2008032077A1 (fr) Dérivés de pyrimidine
US20090270390A1 (en) Pyrimidine derivatives
US20100022534A1 (en) 2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032091A1 (fr) Dérivés de pyrimidine
WO2008032089A1 (fr) Dérivés de 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine utilisés comme inhibiteurs de p13k et de mtor pour le traitement de troubles prolifératifs
WO2008032027A1 (fr) Dérivés de pyrimidine
WO2008032033A1 (fr) Dérivés de 4-benzimidazolyl-2-morpholino-6-pipérazinylpyrimidine utilisés en tant que pi3k et inhibiteurs de mtor destinés au traitement de troubles prolifératifs
WO2007066103A1 (fr) Dérivés de pyrimidine utilisés comme inhibiteurs de la pi3k de classe i
WO2008032060A1 (fr) Dérivés de 4-benzimidaz0lyl-6-m0rph0lin0-2-pipérazinylpyrimidine utilisés comme inhibiteurs de p13k et mtor dans le traitement de troubles prolifératifs
AU2008273892A1 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2008032036A1 (fr) Dérivés de 6-benzimidazolyl-2-morpholino-4-(azétidine, pyrrolidine, piperidine ou azépine) pyrimidine comme inhibiteurs de pi3k et mtor pour le traitement de troubles prolifératifs
WO2006005918A1 (fr) Pyrimidines 2,4,6-trisubstitutees utilisees comme inhibiteurs de phosphotidylinositol (pi) 3-kinase et leur utilisation dans le traitement du cancer
WO2008032041A1 (fr) Dérivés de la pyrimidine à activité inhibitrice contre les enzymes pi3k

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780018590.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07732879

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 9341/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009511568

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12301722

Country of ref document: US

Ref document number: 2007732879

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE